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ABSTRACT
Designing Cell-Free Protein Synthesis Systems for Improved
Biocatalysis and On-Demand, Cost-Effective Biosensors
Mehran Soltani Najafabadi
Department of Chemical Engineering, BYU
Doctor of Philosophy
The open nature of Cell-Free Protein Synthesis (CFPS) systems has enabled flexible
design, easy manipulation, and novel applications of protein engineering in therapeutic production,
biocatalysis, and biosensors. This dissertation reports on three advances in the application of CFPS
systems for 1) improving biocatalysis performance in industrial applications by site-specific
covalent enzyme immobilization, 2) expressing and optimizing a difficult to express mammalian
protein in bacterial-based CFPS systems and its application for cost-effective, on-demand
biosensors compatible with human body fluids, and 3) streamlining the procedure of an E. coli
extract with built-in compatibility with human body fluid biosensors.
Site-specific covalent immobilization stabilizes enzymes and facilitates recovery and reuse
of enzymes which improves the net profit margin of industrial enzymes. Yet, the suitability of a
given site on the enzyme for immobilization remains a trial-and-error procedure. This dissertation
reports the reliability of several design heuristics and a coarse-grain molecular simulation in
predicting the optimum sites for covalent immobilization of a target enzyme, TEM-1 β-lactamase.
This work demonstrates that the design heuristics can successfully identify a subset of favorable
locations for experimental validation. This approach highlights the advantages of combining
coarse-grain simulation and high-throughput experimentation using CFPS to efficiently identify
optimal enzyme immobilization sites.
Additionally, this dissertation reports high-yield soluble expression of a difficult-toexpress protein (murine RNase Inhibitor or m-RI) in E. coli-lysate-based CFPS. Several factors
including reaction temperature, reaction time, redox potential, and presence of folding chaperones
in CFPS reactions were altered to find suitable conditions for m-RI expression. m-RI with the
highest activity and stability was used to develop a lyophilized CFPS biosensor in human body
fluids which reduced the cost of biosensor test by ~90%. Moreover, an E. coli extract with RNase
inhibition activity was developed and tested which further streamlines the production of CFPS
biosensors compatible with human body fluids.
Keywords: Mehran Soltani; cell-free protein synthesis; cell-free; CFPS; in vitro;TEM-1 βlactamase; unnatural amino acid; protein engineering; site-specific; covalent immobilization;
design heuristics; biosensor; murine RNase inhibitor; m-RI; RNase inhibitor; body fluids; urine;
saliva; serum; glutamine; lyophilized; point of care; GroEL/ES; E. coli extract; simulation, pAz
ii

ACKNOWLEDGMENTS
First, I would like to thank my entire family, especially my wife, Roya, for her constant
support, patience, life-changing lessons, and encouragement. I would like to acknowledge my
parents and my brother back in my country, Iran, for their constant support and encouragement.
I would like to thank my advisor, Dr. Brad Bundy, for his mentorship, encouragement, and
help. I also thank our collaborator in coarse-grain simulation, Dr. Tommy Knotts, for sharing his
knowledge, guidance, and time. I would like to thank my graduate committee members Dr. Steve
Johnson, Dr. Josh Price, Dr. Randy Lewis, and my former committee member, Dr. Cook, for their
time, insight, and valuable comments and suggestions.
I am grateful for the help I received from all of the Bundy lab members especially my
teammates and fellow graduate students Addison Smith, Porter Hunt, Emily Zhao, and Tyler Free,
for their friendship, support, guidance, paper edits, and significant contributions to my research. I
also thank exceptional undergraduate students Brady Davis, Landon Ebbert, Sydney Law, Andrew
Nelson, Hayley Ford, Ryan Tucker, and Conner Earl for their help and friendship. I would like to
acknowledge the Chemical Engineering department at BYU for providing the opportunity to study
and learn. I also thank other Ira A. Fulton College of Engineering staff including but not limited
to Bryant Brown, Steve McLean, Serena Jacobson, Arlene Cleverly, and Ed Corbertt for their help
and advice.
This work was funded by the National Science Foundation DMR Division Award (Grant
number: 1710574), the National Science Foundation CBET Division CAREER Award (Grant
number: 1254148), and the National Institute of Biomedical Imaging and Bioengineering (Award
#: 3U54HL143541-02S1). I acknowledge Dr. Dong-Myung Kim (Chungnam National University)
for his generous gift of the pOFX plasmid, Dr. Peter Schultz (Scripps Research Institute) for his
generous gift of the pEVOL-AzF plasmid, and the Fulton Super Computing Laboratory at BYU
for computational resources. BioRender.com was used to create all the schematic figures in this
report.

iii

TABLE OF CONTENTS
LIST OF TABLES ………………….………………………………………...……..............…...vi
LIST OF FIGURES …………….……………………………………………………....…….... vii
1

INTRODUCTION ................................................................................................................... 1
1.1

Overview .......................................................................................................................... 1

1.2

Scope of the Projects ........................................................................................................ 2

1.2.1

Orientation-controlled immobilization of enzymes by CFPS ................................... 3

1.2.2

Low-cost on demand CFPS biosensor for human body fluids ................................. 6

1.2.3

Streamlined E. coli extract preparation with RNase inhibition activity ................... 7

1.3

Outline .............................................................................................................................. 9

2 Assessing the Predictive Capabilities of Design Heuristics and Coarse-Grain Simulation
Toward Understanding and Optimizing Site-Specific Immobilization of β-lactamase ................ 11
2.1

Introduction .................................................................................................................... 11

2.2

Materials and methods ................................................................................................... 14

2.2.1

Extract preparation .................................................................................................. 14

2.2.2

Plasmid preparation and site selection screening.................................................... 15

2.2.3

CFPS reaction ......................................................................................................... 18

2.2.4

Protein purification and characterization ................................................................ 18

2.2.5

Immobilization ........................................................................................................ 19

2.2.6

Activity assay and stability assessment .................................................................. 20

2.3

2.3.1

CFPS screening and AzF incorporation into TEM-1 variants ................................ 20

2.3.2

Activity of TEM-1 mutants after AzF incorporation .............................................. 22

2.3.3

Immobilization ........................................................................................................ 25

2.3.4

Activity and stability assessment of immobilized enzymes ................................... 26

2.3.5

Comparison of predictive heuristics with experimental results .............................. 28

2.4
3

Results and discussion.................................................................................................... 20

Conclusion...................................................................................................................... 30

Rapid RNase Inhibitor Production for Low-cost, On-demand Biosensors in Body Fluids .. 31
3.1

Introduction .................................................................................................................... 31

3.2

Materials and methods ................................................................................................... 34

3.2.1

Extract preparation .................................................................................................. 34
iv

3.2.2

DNA Plasmid preparation ....................................................................................... 35

3.2.3

CFPS reaction and m-RI activity assessment ......................................................... 35

3.2.4

Glutamine biosensor ............................................................................................... 38

3.3

3.3.1

m-RI soluble expression yields ............................................................................... 38

3.3.2

m-RI activity ........................................................................................................... 43

3.3.3

Stability of m-RI ..................................................................................................... 46

3.3.4

CFPS-produced m-RI restores CFPS production in body fluids ............................ 49

3.3.5

CFPS-produced m-RI enables glutamine biosensor in human saliva ..................... 51

3.4
4

Conclusion...................................................................................................................... 54

Streamlining CFPS Biosensors for Human Fluids: in situ RNase Inhibitor in Extract ......... 55
4.1

Introduction .................................................................................................................... 55

4.2

Materials and methods ................................................................................................... 58

4.2.1

Extract preparation .................................................................................................. 58

4.2.2

CFPS ....................................................................................................................... 59

4.2.3

Assessment of the RNase inhibition activity of m-RI extracts ............................... 61

4.2.4

RNase Inhibition activity of mRI extracts in lyophilized CFPS in human fluids ... 62

4.2.5

Glutamine biosensor ............................................................................................... 62

4.3

Results and discussion.................................................................................................... 63

4.3.1

Quantifying the impact of RNase addition on CFPS protein yields ....................... 63

4.3.2

Overexpression of m-RI in E. coli extract and RNase inhibition activity .............. 64

4.3.3

RNase inhibition activity of m-RI+pOFX extract in CFPS with human fluids ...... 72

4.3.4

Saliva-based glutamine biosensor ........................................................................... 73

4.4
5

Results and discussion.................................................................................................... 38

Conclusion...................................................................................................................... 74

Conclusion and future works ................................................................................................. 76
5.1

Conclusion and future works for site-specific covalent immobilization of enzymes ... 76

5.2

Conclusion and future works for RNase inhibitor synthesis with CFPS ...................... 78

5.3

Conclusion and future works for RNase production in CFPS extract preparation ........ 79

REFERENCES ………………..………………………………………………………………………………………………….….81
APPENDIX A …………………………………………………………………………………………………………….…………..97
APPENDIX B ……………………………………………………………………………………………………………………….106

v

LIST OF TABLES
Table 1-1: Work summary and outline ......................................................................................... 10
Table 2-1: Scoring heuristics for UAA incorporation and immobilization.. ................................ 16
Table 2-2: Combined experimental score ..................................................................................... 29

vi

LIST OF FIGURES
Figure 1-1: Schematic representation of a CFPS reaction workflow ............................................. 1
Figure 1-2: Schematic representation of the workflow of site-specific covalent immobilization .. 4
Figure 2-1: Schematic representation of all 17 selected locations in TEM-1 (PDB: 1XPB). ...... 17
Figure 2-2: SDS-PAGE for full-length soluble TEM-1 variants containing AzF. ....................... 21
Figure 2-3: TEM-1 expression yields of variants containing AzF. .............................................. 22
Figure 2-4: Specific activity of TEM-1 variants after AzF incorporation. ................................... 23
Figure 2-5: Immobilization efficiencies for TEM-1 variants. ...................................................... 26
Figure 2-6: Specific activity of TEM-1 variants after AzF incorporation. ................................... 27
Figure 2-7: Comparison of experimental screening and predicted screening............................... 28
Figure 3-1: Soluble m-RI expression yields in presence of GroEL/ES chaperones. .................... 40
Figure 3-2: Soluble m-RI expression yields in absence of GroEL/ES chaperones ...................... 42
Figure 3-3: SDS-PAGE for m-RI. ................................................................................................ 43
Figure 3-4: Schematic illustration of CFPS with m-RI (fresh) and its activity in saliva. ............. 44
Figure 3-5: RNase inhibition activity of the m-RI variants after two freeze-thaw cycles. ........... 47
Figure 3-6: RNase inhibition activity of the m-RI variants (expressed w/ or w/o GroEL/ES). ... 48
Figure 3-7: sfGFP expression in presence of m-RI expressed in CFPS and in human fluids ...... 50
Figure 3-8: Glutamine CFPS biosensor response in presence of saliva or water ......................... 53
Figure 4-1: sfGFP expression in presence of RNase A in absence of any RNase inhibit. ........... 64
Figure 4-2: sfGFP expression of m-RI/Regular extracts in presence and absence of RNases ..... 66
Figure 4-3: Growth curves for m-RI + pOFX extracts. ................................................................ 66
Figure 4-4: sfGFP expression of m-RI + pOFX extracts in absence of RNases........................... 67
Figure 4-5: sfGFP expression of regular and mRI+pOFX extracts supplemented by T7RNAp .. 68
Figure 4-6: sfGFP expression of combined regular and m-RI+pOFX extracts in saliva.............. 69
Figure 4-7: sfGFP expression of combined regular and m-RI+pOFX extracts in RNase A ........ 71
Figure 4-8: sfGFP expression of lyophilized CFPS reactions in presence of human fluids ......... 72
Figure 4-9: Glutamine CFPS biosensor assay. ............................................................................. 74
Figure 4-10: Schematic representation of CFPS biosensor working with body fluids ................. 75

vii

1

1.1

INTRODUCTION

Overview
Cell-free protein synthesis (CFPS) is in vitro protein synthesis enabled by including

transcription and translation machinery of cells harvested from lysed cells or adding transcription
and translational components separately in a PURE format [1, 2]. Additionally, required
components to energize the system (small molecules mix), DNA template (in a plasmid or linear
expression template forms), and C-Leucine to radiolabel the expressed protein for quantification
purposes are supplied in the CFPS reaction as is shown in Figure 1-1.

Figure 1-1: Schematic representation of an E. coli-lysate based CFPS reaction followed by scintillation
counting and an activity assay
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Eukaryotic-lysate-based systems (CHO cells, tobacco, and wheat germ embryos) can
achieve post-translational modifications and high expression of complex proteins [1]. However,
E. coli-lysate-based CFPS systems have numerous advantages including being relatively simple,
cost-effective, rapidly grown, high-yielding, and well-studied [3].
Application of CFPS system for high-throughput protein expression and analysis in an E.
coli-based CFPS enables flexible, economic, and rapid experimentation compared to in vivo
expression and analysis. In addition, CFPS allows for easier and faster purification of proteins by
eliminating the need for downstream lysis and clarification steps [4]. CFPS systems also offer
improved solubility of membrane proteins or macromolecules in addition to a higher yield of
protein folding due to less-crowded environments compared to in vivo expression [3]. Moreover,
due to the open nature of CFPS and the eliminated need for cell viability, unnatural amino acids
(UAAs) and orthogonal translation machineries can be added without cytotoxicity concerns, even
for UAAs with limited solubility and membrane transport limited UAAs [1, 5]. Considering all the
advantages provided by CFPS systems, we decided to use this technology for the development of
improved biocatalysis and to make biosensor applications more feasible.

1.2

Scope of the Projects
Here the high-yield, flexible, and accessible nature of CFPS systems were used to 1)

determine several design heuristics for site-specific covalent immobilization of the target enzyme,
TEM-1, using a combined experimental-simulation approach, 2) develop a low-cost, on-demand
biosensor that works in different human body fluids and test its applicability with a previously
developed glutamine biosensor, and 3) streamline the preparation of an E. coli lysate for the
application of on-demand biosensors that work in human body fluids.
2

1.2.1

Orientation-controlled immobilization of enzymes by CFPS
Enzymes are non-toxic, biodegradable, biocompatible, and highly active biological

catalysts with many applications in the chemical, biofuel, textile, agriculture, and pharmaceutical
industries [6-8]. However, enzymes are relatively unstable outside of their native cellular
environments and it is expensive to produce and separate them from their reaction. Immobilization
substantially improves enzyme stability, simplifies downstream purification processes, enables
recovery and reuse, and allows a continuous reaction format for systems with immobilized
enzymes [6, 9, 10].
Covalent immobilization provides higher enzyme stability and lower enzyme leakage
compared to other immobilization methods including entrapment, cross-linking, and non-covalent
adsorption. However, covalent immobilization can destabilize the enzyme because of rigid
attachment which can alter enzyme conformation and reduce its activity. Controlled orientation of
covalently immobilized enzyme can alleviate this issue by screening against immobilization
orientations which considerably decrease enzyme activity and selecting orientations with the
highest activity, stability, and recoverability of enzymes [11-15].
In covalent immobilization by natural amino acids, we are limited to only two amino acids,
lysine and tyrosine for practical purposes [16], but even those amino acids are repeated several
times throughout the protein structure. This results in random, uncontrolled, and heterogeneous
attachments and reduced or completely lost activity [13, 14]. Similarly, targeting C- or N-terminals
may lead to heterogeneous and non-specific immobilization because of similar side chain
functional groups of natural amino acids or may be unsuccessful due to inaccessible termini or
catalytically important residues [16].
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Here, a site-specific UAA incorporation method was used to control oriented covalent
immobilization of the target enzyme, β-lactamase TEM-1 which degrades β-lactam antibiotics.
The incorporated UAA (p-azido-L-phenylalanine or AzF) provides a specific moiety to react with
the dibenzocyclooctyne (DBCO) group of DBCO-agarose beads in a copper-free strain-promoted
azide–alkyne cycloaddition (SPAAC) to immobilize TEM-1 [17, 18] (Figure 1-2).

Figure 1-2: Schematic representation of the workflow of site-specific covalent immobilization of TEM-1
β-lactamase using CFPS

According to several recent reports by the World Health Organization (WHO) [19, 20],
antibiotic resistance is a serious threat to global health and leads to longer hospitalization,
increased treatment costs, and higher mortality. In addition to limiting the consumption of newer
and more effective antibiotics, we can prevent more antibiotic resistance by strict control of
antibiotic spread and environmental contamination. TEM-1 can prevent more antibiotic resistance
and environmental contamination through degradation of residual β-lactam antibiotics [21].
Moreover, immobilization of this enzyme increases its stability and enables easier separation from
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the reaction mixture to be reused again and improve its economic margin over the free enzymes
[22, 23].
Compared to cell-based protein production, CFPS provides higher soluble protein yields,
faster production, expanded scale variability between a few microliters to 100 L [24, 25], more
control and flexibility in design [26-28], and eliminates constrains of cell viability or membrane
transport limitations [29-31]. A previously developed Protein Residue-Explicit Covalent
Immobilization for Stability Enhancement (PRECISE) method [13] was used in combination with
a coarse-grained simulation to narrow potential immobilization sites.
Previously, two well-known research enzymes (sfGFP and T4-lysozyme) have been
immobilized by considering solvent accessible surface area (SASA) as the single design heuristic
[12, 13] Here, 17 immobilization sites were screened by considering seven design heuristics in an
effort to predict a priori which location would be the best for immobilization efficiency, retained
activity, and stability against a denaturant (urea). Coarse-grain simulation was also used to support
the predictive ability of the design heuristics [13, 15, 35, 36].
In the applied coarse-grain simulation each amino acid in the protein was considered as a
“grain” that then interacts with water or other amino acids in the protein. This greatly decreases
the amount of computation time required compared to atomistic simulations that account for each
atom [37-39]. Additionally, a combined predictive score was compared to a combined
experimental score to assess a priori predictive capabilities of our design heuristics to determine
the best locations for covalent immobilization of TEM-1.

5

1.2.2

Low-cost, on-demand CFPS biosensor for human body fluids
Biosensors have been employed in a wide variety of fields for applications including

clinical diagnosis, environmental monitoring, food safety, and biowarfare agent detection [32].
Biosensors commonly provide a highly sensitive, very specific assay; however, many of these
diagnostic devices have slow response times, high operating costs, require trained technicians, and
require immobile lab equipment [33]. Thus, there is a need to develop more rapid, portable, and
inexpensive detection methods.
CFPS is a promising approach to addressing these limitations. Early on, CFPS played an
important role in determining how amino acids are incorporated into proteins and in deciphering
the genetic code [34]. Since this time, researchers have used CFPS for many other applications.
To date, CFPS systems have been applied as (1) a protein production platform for the expression
of diverse therapeutics, vaccines, and industrial biocatalysts [35-41]; (2) a synthetic biology
platform for in vitro chemical biosynthesis [42], synthetic enzyme pathway expression [43, 44],
and nucleic acid circuitry [45, 46]; and (3) a research platform for high-throughput advanced
protein evolution [47-50], protein-polymer and protein-surface conjugation optimization [13, 51,
52], unnatural amino acid incorporation [5, 13, 53-55], protein micro array fabrication [56, 57],
and genome engineering [58, 59].
Recent developments in CFPS systems have further increased the possibility of applying
CFPS technology to biosensors. Some of these recent advances include demonstrating that CFPS
is viable in a wide range of environmental samples including raw sewage, human urine, and human
blood [60-63]; demonstrating that CFPS systems can be lyophilized and maintain activity after
being stored at temperatures as high as 37oC for months [64-66]; demonstrating that on-demand
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paper-based biosensors enable economic, facile distribution, and point-of-care detection of a
variety of targets.
Human fluids such as blood, plasma, serum, saliva, and urine contain circulating biomarkers which
provide inexpensive, accurate, and reproducible diagnosis methods for predicting or monitoring
of treatments/interventions for a variety of diseases and disorders [67, 68].
The overall cost of the biosensors can be reduced by using E. coli-lysate based systems
instead of commercial CFPS reagents [25, 69-71]; however, there have been no reports for an
economic, in-house production and utilization of an effective RNase inhibitor (RI) in CFPS
systems. Here we report an affordable, fast, and effective method for the expression of soluble and
active murine-RNase Inhibitor (m-RI) by an E. coli-lysate-based CFPS platform.
The CFPS environment has been found to retain highly active cytoplasmic reduction
pathways from the native E.coli cytosol [72]. These reduction pathways, in addition to the open
reaction environment for addition of folding chaperones, make CFPS a promising candidate for
highly soluble production of active m-RI.

1.2.3

Streamlined E. coli extract preparation with RNase inhibition activity
One of the main obstacles in widespread application of CFPS biosensors with human body

fluids is the presence of various RNases in human body fluids [73] which reduces reporter protein
expression due to mRNA and tRNA degradation [74]. Addition of RNase inhibitors to a CFPS
system alleviates this issue, but the commercial form of this reagent accounts for ~ 90% cost of an
in-house E. coli-lysate-based CFPS biosensor which is discouraging for mass-production. Here we
present a method to prepare and test extracts with RNase inhibition activities which tolerate
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relevant types and concentrations of RNases present in three human body fluids of saliva, serum,
and urine.
The cost and durability of in-house CFPS platforms per reaction have been continuously
improved by introducing alternative or regenerative energy sources [75-77], utilization of linear
expression templates (LETs) instead of time-consuming cloning and plasmid isolation [78, 79],
and overexpression of needed enzymes or chaperones in the extract instead of adding them
individually to the system in purified forms [80]. T7 RNA polymerase [81, 82], DsbC as disulfide
isomerase [83, 84], GroEL/ES folding chaperones [84, 85], and orthogonal translation machineries
for UAA incorporation [16, 86, 87] are among supplemented components in extracts which have
been introduced to simplify the CFPS reaction without the need of adding individually expressed
and purified components and to reduce the overall cost and reagent dependency of CFPS reactions.
Additionally, one-pot lyophilization of all CFPS reagents substantially facilitates distribution,
point-of-care application, and room-temperature storage of CFPS reactions for on-demand
therapeutic production and more importantly, as biosensors [88, 89].
CFPS biosensors have already been developed for the detection of viruses (Zika and Ebola)
[63, 90], water contaminants [91-93], endocrine disrupting chemicals [61, 74], biomarkers of
infectious diseases [94, 95], and metabolites [62, 96, 97]. Of these, diagnosis and monitoring of
various biomarkers in human body fluids as surrogate outcomes in treatments of diseases or
disorders shortens the approval time by eliminating ineffective experimental treatments, decreases
the cost of drug development especially for phase I and II trials, and increases our knowledge about
different diseases and developments of new treatments [67].
E. coli was considered as it is the most affordable, available, fast-growing, and highyielding platform despite some limitations in post-translational modifications [98]. High
8

expression yields of different sources of RNase inhibitors (RI) in E. coli has been challenging
because of the hydrophobic core of RI and highly reduced forms which result in high aggregation
or inactive RI [99, 100].
In this study the suitable condition for making extract with overly expressed and active mRI (m-RI extract) will be considered by changing growth temperature, co-expression of GroEL/ES
folding chaperones in extracts, and altered reduction potential of E. coli cultures. Due to the high
cost of the commercial RNase activity assay [RNase AlertTM Lab Test Kit (Invitrogen, Waltham,
MA)], we used CFPS to test RNase inhibition activity of m-RI extracts in the presence of different
levels of RNase A or 30% saliva (as the source of RNases) which reduced the cost from more than
$10 for the commercial assay to ~$0.14 for each RNase /RNase inhibition activity test. Lyophilized
CFPS reactions containing m-RI extracts were used with 0-100% concentrations of three human
body fluids of saliva, serum, and urine to determine the compatibility and applicability of m-RI
extracts with lyophilization and on-demand utilization with popular human fluids in diagnosis or
monitoring of diseases [101, 102]. Finally, a glutamine biosensor working in 30% saliva was
developed to further show m-RI extract applicability for detecting glutamine in saliva in the
presence or absence of externally added glutamine. The glutamine biosensor has been developed
recently [97] considering glutamine as a biomarker of a variety of disorders and diseases including
cancer, kidney disease, Alzheimer’s disease, and diabetes [103, 104].

1.3

Outline
This Dissertation focuses on 1) developing combined computational and experimental

design heuristics to control immobilization orientation of a target enzyme and 2) developing a
CFPS biosensors with RNase inhibition activity to work in human body fluids. Most of this
9

Dissertation is based on three peer-reviewed journal publications (two published and one
submitted) which I led, developed, and wrote as the first author (Table 1-1).

Table 1 1: Work summary and outline
Chapter

Publication

Presented innovation

2

Soltani M., et al., 2021, Int. J. of Biolog.

Development of design heuristics for site-specific

Macro. Mol. (Submitted and Revised)

covalent immobilization of TEM-1

Soltani et al., 2021, Biotech. & Bioeng.

Biosensors to work in human body fluids

3

https://doi.org/10.1002/bit.27874
4

Soltani M. and Bundy B.C., 2021, Biochem.

Streamlined extract preparation with RNase

Eng. J.

inhibition activity for CFPS biosensors

https://doi.org/10.1016/j.bej.2021.108158
Referenced

Soltani M., et al., 2018, Biochem. Eng. J.

Review

of

different

mechanisms

throughout

https://doi.org/10.1016/j.bej.2018.06.014

biosensors

Referenced

Hunt JP, et al., 2021, J. of Biotech.

CFPS Glutamine biosensor

throughout

https://doi.org/10.1016/j.jbiotec.2020.09.011

of

CFPS

I also received help from my colleagues which are addressed appropriately at the beginning of
each chapter. Additionally, this dissertation frequently cites other journal publications where I was
a co-author in addition to the main publications.
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2

ASSESSING THE PREDICTIVE CAPABILITIES OF DESIGN HEURISTICS
AND COARSE-GRAIN SIMULATION TOWARD UNDERSTANDING AND
OPTIMIZING SITE-SPECIFIC COVALENT IMMOBILIZATION OF ΒLACTAMASE

Chapter 2 and Appendix A are based on a submitted journal publication in International
Journal of Biological Macromolecules, entitled “Assessing the Predictive Capabilities of Design
Heuristics and Coarse-Grain Simulation Toward Understanding and Optimizing Site-Specific
Covalent Immobilization of β-lactamase” by Soltani et al., 2021. This work was led, performed,
and supervised by me. Coarse-grain simulation was performed in collaboration with former PhD
student Addison Smith from Dr. Knotts group, and with contributions from Porter Hunt and Emily
Long Zhao.

2.1

Introduction
Industrial enzymes accounted for an estimated global market of $6.3 billion in 2021 [105]

and an estimated more than $10 billion revenue in 2024 [106]. Enzymes provide non-toxic,
biodegradable, highly active, and specific reactions compatible with milder reaction conditions [68, 107]. Yet, despite their numerous advantages, enzymes are relatively unstable in their non-native
environment and have high production and separation costs. As one solution to these challenges,
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immobilization of enzymes can improve their thermal and chemical stability while simultaneously
simplifying enzyme separation, recyclability, and compatibility with continuous and fed-batch
operations [9, 10]. Among different immobilization methods, including entrapment, cross-linking,
non-covalent adsorption, and covalent immobilization, the latter is particularly attractive because
of high enzyme stability and lower enzyme leakage compared to other methods [108]. However,
deciding the best location to covalently tether the enzyme remains challenging. Here we seek to
assess the reliability of design heuristics and coarse-grain simulation in predicting the best sites to
covalently immobilize the target enzyme.
The rigid nature of covalent enzyme immobilization and close interactions between the
enzyme and surface can alter the enzyme’s conformation and reduce its activity, especially when
the enzyme is immobilized at random locations [11, 12, 108-110]. A site-specific immobilization
approach enables immobilization at locations that best stabilize the enzyme and have high
conjugation efficiency without reducing the overall activity [11-15]. Site-specific Unnatural
Amino Acid (UAA) incorporation of azido-L-phenylalanine (AzF) enables covalent
immobilization through a biocompatible copper-free strain-promoted azide–alkyne cycloaddition
(SPAAC) reaction between the azide moiety of AzF and DBCO group of the DBCO-agarose beads
[17, 18]. For this study, 2-state folder TEM-1 β-lactamase (Protein Data Bank ID: 1XPB) was
selected as the target enzyme which degrades β-lactam antibiotics.
According to several recent reports by the World Health Organization [19, 20], antibiotic
resistance is one of the most serious health threats facing our world. Antibiotic resistance
increasingly causes a higher burden on our hospitals, higher treatment costs, and higher mortality.
One approach for combating antibiotic resistance is reducing antibiotic contamination in the
environment. For example, trace antibiotics found in waste streams could be degraded by
12

antibiotic-degrading enzymes like β-lactamase [21, 111]. In such applications, reuse and long-term
stability is necessary for cost-effective utilization of β-lactamase [22, 23] which motivates this
work. Other possible β-lactamase immobilization applications include (1): testing for possible
antibiotic contamination in non-penicillin therapeutics and (2): clinical studies or discovering
better β-lactamase inhibitors [23, 112].
To enable the site-specific covalent immobilization of TEM-1 using an UAA approach
described above, we use an E.coli-based CFPS as illustrated in the graphical abstract. Compared
to cell-based protein production, CFPS provides an “open” transcription/translation environment
such that the UAA can be directly added to the system [86, 113] and its incorporation into TEM1 is not hindered by transport through a cell wall [114]. Similarly, other necessary cofactors (such
as Mg2+ and NAD+) and orthogonal translation machineries (tRNA/aminoacyl tRNA synthetase
pair from Methanocaldococcus janaschii) [115, 116] for UAA incorporation can be directly added
to the system [30, 89, 117]. Once the UAA is incorporated at its prespecified location in TEM-1,
the UAA covalently reacts to an immobilization resin by SPAAC. In this work, 17 different
immobilization sites in TEM-1 were experimentally screened.
Prior to the experimental screen, seven design heuristics were applied to the 17 selected
locations in an effort to predict a priori which location would be the best for conjugation
efficiency, retained activity, and stability against a denaturant. Coarse-grain simulation was also
used to support the predictive ability of the design heuristics [4, 12, 13, 118]. Coarse-grain
simulation considers each amino acid in a protein as a “grain” that then interacts with water or
other amino acids in the protein. This greatly decreases the amount of computation time required
compared to atomistic simulations that account for each atom [119-121]. In addition, a combined
predictive score will be compared to a combined experimental score to assess a priori predictive
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capabilities of our design heuristics to determine the best locations for covalent immobilization of
TEM-1.
2.2

Materials and methods

All chemicals were from Cayman Chemicals (Ann Arbor, MI) unless otherwise specified.

2.2.1

Extract preparation
E. coli extract was prepared as previously described [69, 122] with some modifications

using BL21 Star (DE3) harboring pEVOL-AzF plasmid, a kind gift from Prof. Peter Schultz [123].
The cells were inoculated into 5 ml of LB media containing chloramphenicol antibiotic and grown
at 37°C and 280 RPM overnight. Then, the cells were added to 100 ml of 2xYT media (16 g/L
tryptone, 10 g/L yeast-extract, 5 g/L sodium chloride) in a 500 ml baffled flask and incubated at
37 °C and 280 RPM until reaching to an OD600 of 2.0. The culture was then transferred to a 2.5 L
Tunair baffled shake flask (IBI scientific, IA) containing 900 ml of 2xYT culture media. At an
OD600 between 0.5 and 0.7, the culture was induced with 1 ml of 1 M isopropyl β-D-1thiogalactopyranoside (IPTG) and 0.22 g arabinose for the expression of T7 RNA polymerase and
the orthogonal translation machinery for the UAA (AzF) incorporation [115], respectively. The
cells were harvested at the late-log-phase (OD600 ~4.0) and centrifuged at 8,000 RCF for 30 min.
The cells were washed by suspending in 10 ml buffer A per gram wet E. coli cells. Buffer A
contains 10 mM Tris, 14 mM Magnesium Acetate, 60 mM Potassium Glutamate, and 1 mM DTT
(pH= 8.2). After centrifugation at 12,000 RCF for 20 min, the cells were resuspended in buffer A
(1 ml/g cells) and lysed three times at 21,000 psi using an Avestin Emulsiflex B-15 cell disruptor
(Ottawa, Canada) and centrifuged at 12,000 RCF for 30 min. The supernatant was collected and
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incubated at 37 °C for 30 min for residual mRNA degradation, aliquoted, flash frozen in liquid
nitrogen, and stored at -80 °C.
2.2.2

Plasmid preparation and site selection screening
pTwist plasmid harboring TEM-1 β-lactamase (PDB code: 1XPB) gene with a C-terminal

Strep-tag II was codon optimized for expression in E. coli (sequence in Appendix A) and
constructed by Twist Biosciences (San Francisco, CA). It was transformed into E. coli XL1-Blue
chemically competent cells (Agilent Technologies, Santa Clara, CA) for plasmid DNA isolation.
Cells were grown at 37 °C overnight in 200 ml Terrific Broth media (24 g/L yeast extract, 20 g/L
tryptone, 4 ml/L glycerol). Template DNAs were obtained by QIAGEN Plasmid Maxi Kit
(Valencia, CA) according to manufacturer’s instructions. To enable UAA incorporation, the amber
stop codon (TAG) was substituted into the pTwist plasmid harboring TEM-1 at the locations
specified in Table 2-1 using the QuikChange II site-directed mutagenesis protocol (Agilent
Technologies, Santa Clara, CA) with an efficient primer design method by Liu and Naismith [124]
(Table A-1) and constructed by Invitrogen. Amber stop codon substitutions were confirmed by
DNA sequencing. The sites were sorted based on the overall score according to seven heuristics:
solvent accessible surface area (SASA), secondary structure, side-chain orientation of the replaced
site, the type of the first nucleotide after the amber codon (4th nucleotide), bulkiness of the replaced
site, domain stability, and thermal stability. Of these parameters, domain stability and thermal
stability came from a recent coarse-grain simulation report [125]. For simplicity purposes and
based on previously published criteria [4, 50, 120, 121, 125-127], each heuristic was assigned
scores as detailed in Table 2-1.
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Table 2 1: Scoring heuristics for UAA incorporation and immobilization. All sites in TEM-1 with SASA
> 0.2 that do not impede active site function were considered, but only the 17 selected sites were
selected for UAA incorporation and immobilization alongside the wild-type (WT).
Residue

SASA
score a

Secondary
Structure
score b

Side-chain
orientation
score c

4thnucleotide
score d

Residue
bulkiness
score e

Experimental Design Heuristics

Overall
experimental
factor score

Domain
stability
score f

ΔTm score g

Coarse-grain Simulation

Overall
score
including
simulation

N175
6
3
2
4
2
17
3
4
24
Q88
5
3
1
4
3
16
3
5
24
N154
6
2
2
4
2
16
2
4
22
Q269
6
3
2
4
3
18
0
3
21
E28
5
2
2
4
3
16
1
4
21
S52
5
3
2
4
1
15
0
6
21
A227
6
3
2
4
1
16
0
4
20
L201
5
2
2
4
2
15
2
2
19
D254
6
3
2
4
2
17
0
1
18
E197
6
3
2
0
3
14
2
2
18
T114
6
3
2
4
1
16
1
0
17
K192
3
2
2
0
3
10
2
5
17
R93
4
3
1
0
3
11
3
2
16
R43
3
1
2
4
3
13
0
3
16
P62
3
3
2
4
0
12
0
4
16
G87
6
3
0
0
0
9
3
3
15
E281
4
2
2
0
3
11
1
0
12
a) SASA score: 0: SASA=0: 1: 0.01<SASA<0.09: 2: 0.1<SASA<0.19: 3: 0.2<SASA<0.39: 4: 0.4<SASA<0.59: 5: 0.6<SASA<0.79:
6: 0.8<SASA<1
b) Secondary structure score: 1: β-sheets; 2: α-helix; 3: loops
c) Side-chain orientation score: 0: Inward: 1: Sideway: 2: Outward
d) 4th nucleotide score: 0: Pyrimidine: 4: Purine
e) Residue bulkiness score: 0: G, P; 1: S, T, C, A, V; 2: D, N, I, L; 3: R, H, K, E, Q, M, F, Y, W
f) Domain stability: 0=β-domain; 1=Alpha I; 2=Alpha II; 3=Loop I and II [125]
g) ΔTm score: 0: ΔTm< -50°C; 1: -50< ΔTm<-40°C; 2: -40< ΔTm<-30°C; 3: -30< ΔTm<-25°C; 4: -25< ΔTm<-20°C; 5: -20< ΔTm<15°C; 6: -15< ΔTm (Data from [125])

All the sites are shown in Figure 2-1. SASA data were obtained using ASA-View [128]
accessed through the Mizuguchi Laboratory website [129]. As has been reported previously [4],
higher SASA provides more flexibility and lower steric hinderance for immobilization [4, 126].
Sites with SASA<0.2 were excluded from our screening. Active site proximity, side-chain
orientation, and secondary structures were assessed using Chimera [130] and based on several
mutagenesis studies for TEM-1 [131-133]. In this study, only sites away from the active sites and
substrate binding sites were selected except for N175 which is close to the active site but had very
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strong scores in all other design heuristics (Table 2-1). Loops are believed to provide more
flexibility after immobilization compared to more rigid α-helices and β-sheets [120, 121] and
scored accordingly. The domain stability score and the change in enzyme melting temperature
scores are based a coarse-grain molecular simulation of TEM-1 [125].

Figure 2-1: Schematic representation of all 17 selected locations in TEM-1 (PDB: 1XPB) for site-specific
immobilization. Alpha I domain in orange, Alpha II in green, β domain in blue, Loop I in pink, and Loop
II in yellow.

Coarse-grain simulation predicts thermal stability of tethered variants by calculating
changes in heat capacity when increasing temperature. The melting temperature (or temperature at
which the protein unfolds) is determined by a peak in the heat capacity at a given temperature
[121]. The difference between melting point of the variants and the WT is an indicative of relative
stability of variant relative to the WT. To convert ΔTm in K to simulation scores for our heuristics,
we assigned scores in seven levels from 0 for the least stable variants (ΔTm< -50 °C) to 6 (for -15
°C < ΔTm) as are detailed in the Method section of Table 2-1.
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2.2.3

CFPS reaction
In vitro expression of proteins were based on a PANOx-SP system as described previously

[16, 26] with the following modifications. All reactions contained 35% (v/v) E. coli pEVOL-AzF
extract, 25% (v/v) small molecule master mix [16, 134], 5.25 µM 14C-labeled Leucine (Moravek
Inc., Brea, CA), 3 mM p-azido-L-phenylalanine (AzF) (Chem Impex International, Wood Dale,
IL), 12 mM Mg(Glu)2 (optimized concentration for 35% extract), 72 nM DNA plasmid as the
template, and deionized water for the remaining reaction volume. Because of the sensitivity of
AzF to UV or near-UV light [135], all reactions were assembled under a safe red light and
incubated in darkness. All components were from Sigma-Aldrich unless otherwise specified. All
reactions were performed in triplicates and performed in 65 µl reaction volume in 2 ml
microcentrifuge tubes (GeneMate, BioExpress) at 30 °C, 250 RPM for 14 h. Negative control
reactions without AzF were performed similarly but with 30 µl reaction volumes.

2.2.4

Protein purification and characterization
Liquid scintillation counting was used for the quantification of total and soluble protein

expression yields, immobilization efficiencies, and adjusting enzyme concentrations for the
activity assay as has been explained previously [69, 136]. “Soluble protein” is used to describe the
supernatant (nonaggregated product) of the CFPS reaction mixture after centrifugation at 16,200
RCF for 10 min. Full-length proteins contained a C-terminus Strep-tag II and were purified using
Strep-Tactin® XT Spin Columns (IBA Life Sciences, Gottingen, Germany) according to the
manufacturer’s instructions except that the flow through was returned to the column six times.
120-200 µl 1X BXT buffer (based on soluble expression yield of different variants) was used as
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the elution buffer and returned to the column twice for higher recovery of the purified enzymes.
Purified variants were kept on ice in dark until further use on the same day. Analysis of full-length
or truncated products were done by running 4 µl of the soluble protein before purification on a
NuPAGE 10% Bis-Tris Gel (Invitrogen, Carlsbad, CA) according to manufacturer’s instructions
followed by autoradiography for 2 days as described previously [4].

2.2.5

Immobilization
Purified TEM-1 variants containing AzF were immobilized by the biocompatible copper-

free Strain Promoted Azide-Alkyne Cycloaddition click reaction (SPAAC) between the azide
moiety of the site-specific incorporated AzF and the DBCO group of the pretreated DBCOAgarose beads (Cat. No: 1034-2, Click Chemistry Tools, Scottsdale, AZ). 10 µl of DBCO-agarose
beads was pretreated with 150 µl of 1-2% (w/v) BSA in PBS buffer for 30 min at 37 °C and 280
RPM in 200 µl PCR tubes. After centrifugation at 600 RCF for 2 min, the supernatant was removed
and the beads were washed and vortexed in 150 µl of 1X PBS- 2% Tween® 20 (Sigma-Aldrich)
three times, then washed twice with 150 µl of buffer Z (60 mM Na2HPO4, 40 mM NaH2PO4, 1
mM MgCl2, 10 mM KCl [137]).
Immobilization reactions (n=2) were assembled under a UV-safe red light in 200 µl PCR
tubes containing 142 µg/ml purified TEM-1 (4.7 µM) and 10 µl DBCO-Agarose beads (pretreated) for a final volume of 70 µl, adjusted by buffer Z. The reactions were incubated in the dark
for 5 h at 30 °C and 240 RPM. The beads were centrifuged (600 RCF, 2 min) and the supernatant
was removed. The beads were washed by vigorous mixing with 140 µl buffer W (1X PBS- 2%
Tween® 20- 1% BSA) or buffer Z. The beads were washed 5 times with buffer W, 3 times with
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buffer Z, and finally resuspended in 50 µl of buffer Z. WT TEM-1 was used as a negative control
to assess non-specific attachments. Immobilization efficiency and immobilized protein
concentration were assessed by liquid scintillation counting as described before.

2.2.6

Activity assay and stability assessment
TEM-1 activity was measured by nitrocefin (Cayman chemical, Ann Arbor, MI) as the

substrate with 136 µM nitrocefin and 8 ng/ml enzyme concentration in 105 µl reaction volumes
(n=3). The absorbance-based assay was performed at 30 °C with absorbance at 490 nm taken every
minute over 90 minutes in clear round bottom 96-well plates using a Synergy MX microplate
reader (Biotek Instruments, Winooski, VT). 80 ng/ml enzyme was used for the immobilized TEM1 variants. Stability of free and immobilized enzymes were analyzed by comparing specific
activities before and after urea treatment. For this purpose, free or immobilized enzymes were
treated with 6 M urea at 37 °C for 30 min in 40 µl reactions in 200 µl PCR tubes (placed
horizontally in a shaker incubator, 280 RPM) [138].

2.3

2.3.1

Results and discussion

CFPS screening and AzF incorporation into TEM-1 variants
The aim of this research was to assess optimal attachment sites for the covalent

immobilization of TEM-1 (PDB: 1XPB) onto agarose beads using site-specifically incorporated
AzF. In this research we assessed the predictive capability of seven different heuristics on the 1)
expression level of AzF-containing TEM-1, 2) TEM-1 activity before and after immobilization, 3)
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TEM-1 immobilization efficiency, and 4) immobilized TEM-1 stability after urea treatment. The
seven heuristics (which include SASA, secondary structure, residue bulkiness, 4th nucleotide type,
side-chain orientation, simulated domain stability, and simulated thermal stability) and
corresponding rankings for each of the 17 locations tested are listed in Table 2-1.
As detailed in the Methods section, E. coli-based CFPS was used to incorporate AzF sitespecifically at predetermined locations by amber stop codon suppression. A C-terminal Strep Tag
II facilitated purifying full-length proteins containing site-specifically incorporated AzF. Soluble,
full-length production of TEM-1 variants and site-specific incorporation of AzF was verified by
SDS-PAGE electrophoresis and autoradiogram as shown in Figure 2-2.

Mutation: WT E28 R43 S52 P62 G87 Q88 T114 R93
AzF: -

+ - + -

+ - + -

+ -

+ - + -

+ -

N154 K192 E197 L201

A227 D254

N175 Q269 E281

+

+

+

-

+ -

+

-

+

-

-

+

-

-

+ -

+ -

Figure 2-2: SDS-PAGE for full-length soluble TEM-1 variants containing AzF (+) and truncated or misincorporated TEM-1 variants (-) in absence of AzF. In absence of AzF, truncation at the amber stop
codon as well as low levels of tyrosine, phenylalanine, tryptophan, or glutamine misincorporation have
been described previously [139]. However, in the presence of AzF the amber stop codon is suppressed
and AzF is incorporated with high selectivity [54, 123, 140, 141].

Figure 2-3 reports the total and soluble expression yields of C14-radiolabled TEM-1 after
14 h CFPS reaction at 30 °C. As has been reported previously [4, 50, 142], expression yields for
UAA incorporation is lower compared to the WT and varied with AzF incorporation location.
Incomplete amber stop codon suppression results in early termination of translation and truncated
products [50]. In this work, soluble expression yields for AzF incorporation were between 70 and
700 µg/ml which corresponds to between 9 and 86% of WT expression yield.
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AzF Substitution Location

Figure 2-3: TEM-1 production yields for wild-type and mutants containing AzF. Error bars represent one
standard deviation for n=3 CFPS reactions. Dark bars represent the total production yield and white bars
represent the soluble yield as determined by C14-radiolabeling.

Analysis of results shows that total expression yields for purine as the first nucleotide after
the amber stop codon (4th nucleotide) results in higher total yields compared to pyrimidine with a
p-value of 0.026 using a t-test (Figure A-1). This result confirms a correlation between the “4th
nucleotide” predictive heuristic and total expression which has been reported previously [50, 143,
144] and attributed to the interaction of release factors and ribosome release strength [50, 143]. As
expected, a significant correlation was not observed between TEM-1 expression yields and the
protein structure design heuristics SASA, secondary structure, side-chain orientation, domain
stability, and residue bulkiness (p > 0.05, Figure A-2).

2.3.2

Activity of TEM-1 mutants after AzF incorporation
Activity of TEM-1 variants with AzF incorporated at different locations were assessed with

a nitrocefin substrate at 30 °C for 90 minutes. TEM-1 hydrolyzes nitrocefin shifting its UV/Vis
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absorbance peak. Figure 2-4-A reports the specific activities of soluble AzF-incorporated TEM-1
relative to WT TEM-1. The activities of AzF-containing TEM-1 varied between 10 and 100% of
WT activity. Specific activities of Q88AzF, R93AzF, N154AzF, and L201AzF remained like WT.

A

B

4

Specific Activity (μM/ng/min)

3.5
3
2.5

C

2
1.5
1
0.5
0

AzF Substitution Location

Figure 2-4: A) Specific activity of WT and TEM-1 mutants after AzF incorporation and purification (in
µM Product/ng Enzyme/min) at 30 °C after 2000 s. Error bars represent one standard deviation for n=3
activity assays. Bar colors correlate with TEM-1 domains. B) Schematic representation of TEM-1 (PDB:
1XPB) domains [125] and residues involved with the active site (in red). Alpha I domain in orange, Alpha
II in green, β domain in blue, Loop I in pink, and Loop II in yellow. C) Domain stability effect on the
specific activity of TEM-1 variants containing AzF (in µM Product/ng Enzyme/min).

Simulated domain stability was the single most important factor among tested heuristics
determining the activity of free TEM-1 mutants. For reference, all domains are designated by color
in Figure 2-4-B with Alpha I domain in orange, Alpha II in green, β domain in blue, Loop I in
pink, and Loop II in yellow- as has been defined previously according to a coarse-grain simulation
[125]. Residues 70, 73, 130, 166, 234, and 235 were reported to be involved in TEM-1 activity
[145, 146] and are shown in red (Figure 2-4-B). Analysis of the specific activity of mutants shows
higher retained activity for replaced residues in Loop I (Q88, R93, G87, T114) and Alpha II (N154,
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L201, K192), compared to Alpha I (E281, E28) or β (R43, D254, P62, A227, S52, Q269) domains
with a p-value of 0.011 (Figure 2-4-C). Despite expected high stability of the Loop II domain,
N175AzF of Loop II had the worst specific activity of all TEM-1 AzF incorporated variants. This
is not surprising considering that N175 residue is part of the omega loop (residues 164-179) which
is essential to the enzyme’s hydrolyzing activity [132, 133] and further verifies that locations
involved in the enzyme activity are poor targets for mutation and immobilization. Thus, if the
specific residues involved in enzyme activity are not known, experimental validation will always
be required.
It is generally hypothesized that mutants far from an active site will likely have reduced
impact on activity. For TEM-1, the Alpha I domain is relatively far from the active site.
Interestingly, AzF incorporations at locations in the Alpha I had lower activities compared to sites
in the Loop I and Alpha II domains which are closer to the active site. This observation is in
accordance with the coarse-grain simulation of TEM-1 (PDB: 1XPB) by Smith et al. [125] wherein
the authors ranked the domains with different thermal stabilities from highest to lowest stability
as Alpha II, Loops, Alpha I, and β domains. Thus, while residues involved in enzyme activity are
generally not effective sites for mutation or immobilization, the distance from active site does not
appear to clearly correlate with a location’s ability to tolerate mutation or immobilization.
We also found a correlation between the soluble fraction of expressed TEM-1 mutants and
their specific activities in the free forms; further supporting a stability component to TEM-1
activity. TEM-1 variants containing AzF with lower levels of soluble protein expression also had
lower specific activities (Figure A-3). Thus, soluble expression levels alone may be effective at
eliminating mutants with lower activities as has been recommended previously for T4-lysozyme
[4]. Secondary structure, SASA, and residue bulkiness were not effective parameters in predicating
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specific activity (Figure A-4). R43AzF and N175AzF variants had very low levels of both soluble
expression and specific activity and were thus eliminated from further consideration.

2.3.3

Immobilization
The AzF-incorporated TEM-1 were immobilized onto pretreated DBCO-Agarose beads by

SPAAC reaction at 30 °C for 5 hr. Non-specific interactions of target enzyme with the agarose
beads were prevented by preincubating the agarose beads with blocking reagent BSA [147-149].
Pre-treatment of beads with 1% (w/v) BSA reduced non-specific absorption of WT TEM-1 to the
DBCO-beads from 20% to less than 3% while still enabling covalent attachment of TEM-1
containing the AzF moiety.
Figure 2-5 reports immobilization efficiencies of TEM-1 variants (bars) relative to the
maximum theoretical immobilization efficiency for 100% immobilization based on DBCO residue
prevalence on beads per manufacturer’s specifications (dashed line). Immobilization efficiencies
(in mg enzyme/g beads) were between 35-82% of the maximum immobilization efficiency for
TEM-1 variants containing AzF compared to ~3% for the WT which does not contain AzF.
This study considered SASA as a potential predictor within the site-selection design
heuristics. This study revealed that the 3 immobilization locations with the highest immobilization
efficiency all had a SASA calculated as greater than 0.95, strengthening the potential for SASA as
a predictor of immobilization efficiency. Interestingly, the 3 locations with the lowest
immobilization efficiencies also had SASA greater than 0.6, with the 2nd lowest immobilization
variant D254AzF having an SASA of 1.0. Thus, a strong correlation cannot be drawn between
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SASA and immobilization efficiency, and more research is needed to determine if SASA is a good
heuristics for a priori immobilization efficiency.
TEM-1 Immobilization Yield

Maximum Theoretical Yield

TEM-1 Immobilization Efficieny (mg/g Beads)

1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
AzF Substitution Location

Figure 2-5: Immobilization efficiencies for wild-type and TEM-1 mutants (mg Enzyme/g beads). Error
bars represent one standard deviation for duplicate tests.

A clear correlation between immobilization efficiency and other heuristics (secondary
structure, SASA, side-chain orientation, side-chain bulkiness, and domain stability) were not found
(p > 0.05, Figure A-5).

2.3.4

Activity and stability assessment of immobilized enzymes
The activities of the immobilized enzymes were measured as described in Methods.

Specific activity of all immobilized TEM-1 variants (in µM Product/µg beads/min) are shown in
Figure 2-6. In contrast to free TEM-1, immobilized enzymes show a narrower range of specific
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activities between 0.06-0.13 µM Product/µg beads/min. N154, Q269, and K192 had the highest

Immobilized TEM-1 Activity (μM/μg Beads/min)

immobilized activities.

Immobilized

0.18

Immobilized, Post Urea Treatment

0.16

*

0.14
0.12

*

0.1

*

0.08
0.06
0.04
0.02

*

0
AzF Substitution Location

Figure 2-6: Specific activity of immobilized TEM-1 mutants (µM Product/µg beads/min) before and after
urea treatment (6 M urea at 37 °C for 30 min). Error bars represent one standard deviation for at least 3
replicates. Locations with significant reductions in specific activity (p < 0.05) are specified by asterisks.

Stability was assessed by treating all free and immobilized TEM-1 variants in 6 M urea at
37 °C for 30 min. The activity of all free variants was undetectable after urea treatment (Figure A6). In contrast, immobilized variants retained between 55% to 100% of their pretreatment
activities, with 80% of TEM-1 immobilized variants completely retaining their original activities
(Figure 2-6). The three variants with decreased activity after urea incubation (p < 0.05) are
specified by asterisk. Among different parameters, higher soluble percentage of the expressed
mutants, which correlates with higher specific activity, seems to correlate to some degree with the
higher stability of immobilized enzymes following urea treatment (Figure A-7). Similarly, coarse-
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grain simulation of immobilized enzymes and the corresponding simulated change in melting point
correlates to some degree with immobilized enzyme stability after urea treatment (Figure A-8).

2.3.5

Comparison of predictive heuristics with experimental results
Figure 2-7A reports the correlation between the combined score of the predicted heuristics

described previously (Table 2-1) and the combined score of the experimental results (Table 2-2).
To delineate the impact of the coarse grain simulation results, this correlation is performed on two
sets of data where one includes the predicative heuristics including the coarse grain simulation
(orange markers) and the other does not include coarse grain simulation predictions (blue markers).

B

A
Experimental vs. Prediction Excluding Simulation
Experimental vs. Prediction Including Simulation

Experimental Overall Score

23

N154

21

Q269

Q269

Q88

19

N154
Q88

17
15
13
11
9

9

11

13

15

17

19

21

23

Predicted Overall Score

Figure 2-7: A) Comparison of experimental screening and predicted screenings in presence or absence of
thermal stability screenings determined by a coarse-grain simulation. For the prediction including thermal
stability calculated by the coarse-grain simulation, y=0.871x and R2=0.97. For the prediction without
coarse-grain simulation, y=1.041x and R2=0.97. B) Illustration of the location of the best location on
TEM-1 for immobilization based on experimental results (N154, Q269, and Q88 respectively).

While the correlation is not perfect, it is impressive that the top three sites for
immobilization of TEM-1 (N154, Q269, and Q88 as are shown in Figure 2-7B) as determined by
28

experiment, matched the top three sites predicted by the combined design heuristic score both with
and without coarse grain simulation results.
The coarse grain simulation was effective in predicting the stability of the protein domains
by a single simulation of the WT TEM-1; however, it was less effective at predicting the locational
immobilization impact on TEM-1 stability when challenged against denaturant urea. Indeed, the
simulation predicted S52 to be the best thermally stabilized immobilization location [125] (Table
2-1); however, S52 was one of the three sites that decreased in activity after urea treatment (Figure
2-6).

Table 2 2: Combined experimental score. The immobilization locations are listed with top performing sites
listed first.
TEM-1
Variant
N154
Q269
Q88
E197
K192
E28
A227
L201
G87
E281
P62
T114
D254
R93
S52
WT
R43
N175

Relative
Soluble
Expression
0.5
0.6
0.4
0.2
0.4
0.9
0.7
0.5
0.3
0.5
0.3
0.4
0.5
0.1
0.2
1
0.2
0.1

Relative
Free
Enzyme
Activity
0.9
0.7
1
0.7
0.7
0.4
0.6
0.9
0.7
0.3
0.5
0.7
0.5
1
0.6
1
0.3
0.2

Relative
Immobilization
Yield
1
0.9
0.8
1
0.9
0.8
1
0.5
0.7
0.7
0.7
0.7
0.5
0.6
0.4
0
-

Relative Activity
After
Immobilization
1
0.9
0.8
0.8
0.8
0.6
0.5
0.6
0.6
0.8
0.8
0.5
0.5
0.5
0.6
0.1
-

Relative
Activity Post
Urea
Treatment
1
0.7
0.8
0.9
0.8
0.8
0.7
0.8
0.7
0.7
0.7
0.6
0.8
0.3
0.4
0.1
-

Overall
Score
22
19
19
18
18
17.5
17.5
16.5
15
15
15
14.5
14
12.5
11
11
2.5
1.5

This is not entirely surprising considering the coarse grain simulation is assessing thermal
stability rather than chemical stability with the mechanisms differing to some degree for high
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concentrations of the denaturant [150, 151]. Future work parameterizing the denaturant such that
it could be included in a coarse grain simulation would likely improve its predictive capabilities.

2.4

Conclusion
This study examines several design heuristics including SASA, secondary structure, side-

chain orientation, and bulkiness of the replaced residue for predicting a priori the best locations
for covalently immobilizing TEM-1 β-lactamase. A CFPS approach was used for high-yield, rapid,
and economical expression of different variants containing an AzF for site-specific immobilization
onto agarose beads. Interestingly, the nucleotide following the amber stop codon substitution (4th
nucleotide) was a statistically significant predictor of the CFPS product yield. Importantly, the
relative stability of each structured domain of TEM-1 as determined by a coarse grain simulation
[125] was predictive of the impact of incorporating the AzF on the activity of TEM-1. This is
particularly useful as domain stability can be achieved by only a single coarse-grain simulation of
the wild-type target enzyme which is extremely time-efficient and simple compared to the
simulation of thermal stability of tethered enzymes. Overall, the combined heuristic approach
applied herein was correlated well enough to predict the top three optimal immobilization locations
on the 2-state folding protein TEM-1. We anticipate that these results will assist investigators in
designing and creating highly active and cost-effective immobilized enzyme biocatalysts for
chemical, agricultural, and pharmaceutical applications.
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3

RAPID RNASE INHIBITOR PRODUCTION TO ENABLE LOW-COST, ONDEMAND CFPS BIOSENSOR USE IN HUMAN BODY FLUIDS

Chapter 3 and Appendix B are based on a published peer-reviewed journal publication in
Biotechnology and Bioengineering, entitled “ Rapid RNase Inhibitor Production to Enable Lowcost, on-Demand Cell-Free Protein Synthesis Biosensor use in Human Body Fluids” by Soltani
M., Hunt J.P., Bundy B.C., 2021 (https://doi.org/10.1002/bit.27874). This work was conceived,
led, performed, analyzed, and supervised by me with contributions from former PhD student J.
Porter Hunt and Dr. Brad Bundy in design of the experiments, analysis of data, and manuscript
edition and revision.

3.1

Introduction
Human body fluids such as blood, plasma, serum, saliva, and urine contain myriad

biomarkers which enable medical diagnosis, streamline and enhance drug discovery and approval,
facilitate monitoring of treatment progress, and increase fundamental understanding of a variety
of diseases and disorders [67, 68]. Unfortunately, detection of biomarkers often requires (1)
expensive, centralized equipment, (2) large sample volumes, and (3) lengthy assays which
escalates medical costs and constrains utility. Economic, rapid, and point-of-care biosensors could
help transform medical care.
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CFPS is a rapid, high-yielding, and flexible platform for producing a variety of products
including pharmaceuticals and biosensors [44, 66, 152, 153]. Lyophilized CFPS reactions in a
single-pot are shelf-stable at room temperature for months [64, 154] until activated by the addition
of an aqueous sample for point-of-care applications [89, 153, 155]. For example, CFPS is a
promising platform for distributed therapeutic production [69, 156-158]. Additionally, lyophilized
biosensors may enable facile and economic point-of-care detection of a variety of targets in human
fluids including Ebola [90], Zika [63], Norovirus [159], microRNAs [160], natural and synthetic
hormones [61, 74], and amino acids [62, 97]. The overall cost of CFPS biosensors is substantially
reduced by using E. coli-lysate based systems prepared in-house instead of commercially available
PURE or lysate-based CFPS reagents [25, 69]; however, there has been no reports for an economic,
in-house production and utilization of an effective RNase inhibitor (RI) in CFPS systems. Here we
report an optimized platform for the expression of highly soluble and active RI in an E. coli-lysatebased CFPS system to reduce the reagent costs of CFPS biosensors by ~90% (Cost analysis of
CFPS biosensors, Appendix B).
Because of its inexpensive, fast growing and yet robust nature, E. coli is one of the most
convenient and widely used hosts for recombinant protein production [161]. However, highyielding recombinant expression of properly folded RI in E. coli has been proven challenging due
to the highly reduced and hydrophobic core of RI proteins. In vivo expression of RI in E. coli has
resulted in high aggregation and low soluble yields of 0.25-15 µg/mL [99, 162]. Furthermore,
solubilization of these insoluble aggregates is inefficient, time and labor intensive, and difficult
[163]. Fusion partners may improve in vivo expression, but these decrease RI activity and require
post-expression processing for removal of the tag [164, 165]. Likewise, lower fermentation
temperatures and reducing environments may increase soluble yield, but these cripple E. coli
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growth kinetics. [166] Improved techniques for synthesis of recombinant RI are highly desirable
to enable economic, point-of-care detection of biomarkers in human fluids with CFPS.
Here we report an optimized platform for the expression of highly soluble and active
recombinant murine RNase inhibitor (m-RI) in an E. coli-lysate-based CFPS system to reduce the
reagent costs of human-fluid CFPS biosensors by ~90%. This platform leverages the open nature
of the CFPS reaction environment and residual cytosolic reduction pathways [72] to incorporate
folding chaperones and manipulate redox potential for optimal m-RI folding and achieved soluble
titers approaching 750 µg/ml in 2 h. Then, CFPS reactions expressing sfGFP reporter protein
containing 30% human saliva (which contains high concentrations of RNases) were utilized to
assess the expression-dependent activity of m-RIs to ensure optimal RNase-inhibition as well as
expression yield. Next, the productivity of lyophilized CFPS reactions incorporating highly active
and stable in-house m-RI was assessed in presence of three human fluids (saliva, serum, and urine)
relevant in diagnosis and treatments [167, 168].
Lastly, a lyophilized glutamine biosensor was developed as a proof-of-concept application
for an on-demand saliva-based biosensor. Glutamine is a biomarker for a variety of disorders and
diseases including diabetes, cancer, kidney disease, chronic intestinal pseudo-obstruction, brain
dysfunction, Alzheimer’s disease, major depression, and anorexia nervosa [103, 169, 170]. This
work demonstrates the utility of CFPS systems to elucidate and overcome complex protein folding
requirements, and to provide a distributable, economic platform for rapid, point-of-care biomarker
detection for a variety of disorders and diseases.
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3.2

3.2.1

Materials and methods

Extract preparation
E. coli extracts were prepared using strain BL21-Star (DE3) (Invitrogen, Carlsbad, CA) as

described previously [122] without any additional transformed plasmids (normal extract) or by
transforming GroEL/ES in it (pOFX extract), a kind gift from Dr. Dong-Myung Kim. GroEL/ES
chaperones have been used for proper folding of the target proteins without aggregation or
degradation [171]. All cell cultures were grown at 37 °C and 280 RPM. First, overnight cultures
of 5 ml LB media containing no antibiotic and spectinomycin for the normal and pOFX extracts,
respectively, were added to 100 ml of 2xYT media in 500 ml flasks and grown until an OD600 of
about 2.0. Then, 100 ml cultures were added to 900 ml fresh 2xYT media in 2.5 L Tunair baffled
shake flasks (IBI scientific, IA). At OD600 of 0.6, both cultures were induced by 1 mM final
concentration of β-d-1-thiogalactopyranoside (IPTG). Cells were harvested at the late log phase at
OD600 of 3.7 and 3.0 for the normal and pOFX extracts, respectively. Cells were centrifugated at
8,000 RCF for 20 min, washed (10 mL/g wet cells) then resuspended (0.7 ml/g wet cells) in cold
Buffer A. Buffer A contains 14 mM magnesium acetate, 10 mM tris, 60 mM potassium glutamate,
and 1 mM DTT, pH 8.2. Cells were then homogenized with the Emulsiflex B-15 French press
homogenizer (Avestin, Ottawa, Canada), three passes at 21,000 PSI, with 1 min cooling between
the second and the third pass. Lysed cells were centrifuged at 12,000 RCF for 30 min and the
supernatant was aliquoted, flash-frozen, and stored at -80 °C until single-use.
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3.2.2

DNA Plasmid preparation
pTwist m-RI plasmid harboring the codon-optimized m-RI sequence (Protein Data Bank

ID: 3TSR) for expression in E. coli, was designed and submitted for synthesis by Twist Bioscience
(San Francisco, CA) containing no tag (plasmid sequence in Appendix B). It was transformed into
XL1-blue chemically competent cells (Agilent Technologies, Santa Clara, CA) and the plasmid
insertion was later confirmed by sequencing. A single colony on solid culture media was
inoculated in 5 ml LB media containing ampicillin and grown overnight at 37 °C in a shaker
incubator. Then, 5 ml culture was added to 200 ml of Terrific Broth media (24 g/L yeast extract,
20 g/L tryptone, and 4 ml/L glycerol) in a 500 ml flask and left for at least 16 h before harvesting
in 8,000 RCF for 20 min. QIAGEN Plasmid Maxi Kit (Valencia, CA) was used for plasmid DNA
isolation according to the manufacturer’s instructions. QuikChange II site-directed mutagenesis
(Agilent Technologies, Santa Clara, CA) was used per manufacturer’s instructions to insert 6x-His
tag into either N or C-terminal of the m-RI insert gene and successful insertions were confirmed
by sequencing. All primers were designed according to an efficient method by Liu and Naismith
[124] and all primer sequences are available in Table B-1. The Plasmid PY71-sfGFP was used for
sfGFP expression and its sequence was reported previously [16].

3.2.3

CFPS reaction and m-RI activity assessment
CFPS reactions used PANOx-SP system for energy regeneration as described previously

with some modifications [16]. Reaction volumes for expressing m-RI and testing m-RI activity
were 30 µl and 50 µl respectively in 2 ml round-bottom microcentrifuge tubes (GeneMate,
BioExpress). For m-RI expression, each reaction contained 35% (v/v) E. coli extract (normal or
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pOFX), 25% (v/v) small molecules master mix as previously described [26], 10.5 µM 14C-labeled
Leucine (Moravek Inc., Brea, CA), 9-12 mM magnesium glutamate (concentration adjusted based
on extract for optimum protein expression), 36 nM pTwist m-RI plasmid as the DNA template,
and the balance ultrapure water. Reducing potential for each reaction was adjusted by DTT or
glutathione. Reactions (n=3) were incubated at 15-30 °C for 2-8 h and 280 RPM. Liquid
scintillation counting was used as described previously [16] for quantifying total and soluble
protein expression yields. “Soluble” portion describes the supernatant of the CFPS reaction after
centrifugation at 16,000 RCF for 10 min at 4 °C.
NuPAGE 10% Bis-Tris Gel (Invitrogen, Carlsbad, CA) was used per manufacturer’s
instructions followed by autoradiography for 3 days to confirm correct size of in-house,

14

C-

labeled m-RIs and compare with the standard commercial m-RI (NEB, Ipswich, MA). These inhouse m-RIs were expressed at 24 °C and 2 h under reduced, oxidized, and native CFPS conditions
with pOFX extract.
sfGFP was employed as an indicator protein in CFPS reactions to test m-RI activity. Each
CFPS reaction for sfGFP expression composed of 25% (v/v) normal BL21-Star (DE3) extract,
25% (v/v) small molecules master mix, 18 mM Mg(Glu)2, 2 nM PY71-sfGFP DNA plasmid, 30%
(v/v) saliva (provided by volunteers following IRB approved protocols), and ultrapure water for
the remaining 50 µl reaction volume. The activity of the CFPS-produced m-RI was determined by
adding 1-3 µg/ml soluble unpurified m-RI expressed at different conditions, to CFPS expressing
sfGFP. As a standard for comparison, 1 U/µl reaction commercial m-RI (NEB, Ipswich, MA) was
used. As the positive control (no saliva), deionized water was added instead of saliva and m-RI.
sfGFP expression after 3 h of reaction at 37 °C and 280 RPM was quantified by fluorescence
analysis. 20 µl of CFPS reaction and 45 µl deionized water were added to a black 96-well plate
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and fluorescence was measured by a BioTek Synergy MX (Biotek Instruments, Winooski, VT)
plate reader at 480/510 nm excitation/emission. sfGFP expression was reported either as relative
fluorescence units (RFU) or µg/ml (as determined by comparing RFU levels of known
concentrations of C14-radiolabeled sfGFP).
To determine m-RI stability, similar sfGFP expression reactions in presence of 30% (v/v)
saliva were performed by adding 1-3 µg/ml of unpurified CFPS-produced m-RI after one and two
freeze-thaw cycles. For freeze-thaw cycles, m-RI CFPS reactions were flash-frozen by liquid
nitrogen and kept at -80 °C for at least one day before thawing at room temperature and activity
assessment.
To test m-RI activity in presence of varying amounts (0-100% (v/v)) of three human fluids
of saliva, serum, and urine, CFPS reactions for sfGFP expression were assembled without adding
deionized water or any human fluids. Reactions were flash-frozen by liquid nitrogen and placed in
a freeze-dryer (Labconco FreeZone 2.5L, Kansas City, MO) and lyophilized at -50 °C overnight.
Lyophilized CFPS reactions were stored at -20 °C for at least one week before rehydration with 0100% human fluids.
Saliva and urine samples were donated by volunteers and after aliquoting in smaller
(single-use) volumes, were flash-frozen and stored at -80 °C for consistency purposes. Human
serum samples were obtained from Gemini Bio Products (Sacramento, CA), aliquoted in smaller
volumes, flash-frozen and kept at -80 °C for single use.

37

3.2.4

Glutamine biosensor
For testing glutamine concentration in saliva in presence or absence of externally added

glutamine, CFPS reactions were assembled similar to m-RI activity assessment by sfGFP
expression as previously reported [97] with some modifications. First, CFPS reagents were
deficient in glutamine amino acid. To eliminate background glutamine synthesis by the inherent
glutamine synthetase (GLNS) in E. coli extract, methionine sulfoximine (MSO, 70 mM final
concentration) was added to PANOx-SP to inhibit GLNS as has been recently reported in detail.
To include the effect of lyophilization on m-RI activity, CFPS biosensing reactions which included
the CFPS-produced m-RI as an unpurified CFPS-product were assembled and lyophilized in a
freeze-dryer overnight as described previously [172]. Lyophilized CFPS reactions were stored at
-20 °C for at least one week before rehydration with diluted saliva or ultrapure water (control).
Glutamine was added (0-600 µM final concentration) to the lyophilized CFPS reactions in
presence of deionized water or 20-70% (v/v) saliva and sfGFP expression yields were measured
after 3 h reaction at 37 °C.

3.3
3.3.1

Results and discussion
m-RI soluble expression yields
Eukaryotic RNase inhibitors have internal hydrophobic leucine rich cores and contain 30-

32 reduced cysteine residues which make its soluble and active expression by prokaryotic systems
challenging [164]. To address this challenge m-RI was expressed with E. coli-lysate-based CFPS.
Preliminary expression results at 30°C showed higher soluble expression of m-RI by using a BL21
Star DE3 E. coli extract which contains GroEL/ES chaperones (expressed from the pOFX
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plasmid), compared to the BL21 Star DE3 E. coli extract. This is in accordance with previous
results for in vivo expression of m-RI by E. coli in presence of GroEL/ES chaperones [164]. The
exact mechanism for superior folding of m-RI in presence of GroEL/ES compared to the native
folding machinery of E. coli has not been explored in details but is postulated to be m-RI protection
from oxidation or aggregation within the chaperone cage (passive cage), or involvement of the
cage in folding by limited mobility and interaction of the cage (active cage), or unfolding the
misfolded m-RI within the cage and refolding inside or outside the chaperone cage [164, 171].
All cysteines in m-RI are reduced and interact with RNase substrates [164]. Thus, the
reducing environment of native CFPS reactions was expected to favor this requirement.
Nevertheless, the accessible nature of the CFPS reaction environment facilitated systematic
investigation of the protein synthesis redox potential that yielded optimal soluble expression at
three reaction temperatures and for three reaction durations. Figure 3-1 reports soluble expression
yields of m-RI with two ratios of oxidized (reducing agent) and reduced glutathione (8 mM
GSH/0.5 mM GSSG, 4 mM GSH/1 mM GSSG), two concentrations of the reducing agent DTT (4
and 12 mM), and the native CFPS reaction environment. Each redox condition was tested at three
reaction temperatures of 15°C, 24°C, and 30°C and three batch reaction durations of 2, 6, and 8 h.
Interestingly, a CFPS reaction temperature of 24°C yields the highest soluble titer of m-RI across
all redox conditions (Figure 3-1).
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Figure 3-1: Soluble expression yields of m-RI at 15 °C (blue), 24 °C (green), and 30 °C (brown) after 2,
6, and 8 h reaction, expressed by CFPS in a GroEL/ES enriched extract. Different reduced conditions are
shown in solid (8 mM GSH/0.5 mM GSSG), pale (4 mM GSH/1 mM GSSG), diagonal stripes (12 mM
DTT), horizontal stripes (4 mM DTT), and transparent (Native) using the reaction temperature color.

This observation corroborates several studies which recommend lower reaction
temperature for higher solubility and activity of different recombinant protein expression in E. coli
[173, 174] and yeast cells [175]. Surprisingly, the 30°C reaction temperature is less favorable for
high soluble protein expression than the two lower reaction temperatures despite anticipated faster
reaction kinetics. Indeed, faster expression of the target protein may overwhelm GroEL/ES folding
machineries and lead to more aggregation or misfolding than correct folding of the target protein
[176, 177]. Higher reaction temperature also reduces the solubility of oxygen in the CFPS liquid,
a condition that has been shown to reduce CFPS expression yield [138, 157].
Reaction duration also affected soluble m-RI yield in interesting and explicable ways. At
all conditions tested, soluble yields remained constant or decreased between 6 h and 8 h reaction
duration. This decrease could be attributed to increased time for unproductive protein-protein
interactions that lead to aggregation. The rate of this aggregation is likely more pronounced as the
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protein synthesis rate reaches a maximum then subsequently slows as a result of DNA and mRNA
degradation, depletion of high energy compounds, and accumulation of toxic side products such
as inorganic phosphates [71, 77, 178]. The decline in soluble expression yield after 6 h could also
be attributed to the activity of native E. coli proteases. Notably, protein synthesis reaction rate is
significantly slower at 15 °C.
Consistent with these explanations, the decline in soluble yield over time was most
significant for the higher reaction temperature of 30°C (Figure 3-1, brown bars).
Importantly, soluble expression of m-RI was higher in CFPS reactions supplemented with a
reducing buffer (Figure 3-1, colored/patterned bars) for all times and temperatures except for 15 °C
and 2 h which had comparable soluble yields regardless of reducing potentials. Among the two
reductants, GSH/GSSG combination provided higher soluble expression yields compared to DTT
for most conditions.
The highest soluble m-RI expression was achieved by 8 mM GSH/0.5 mM GSSG at 24 °C
after 6 h (847±64 µg/ml). Nearly 87% of this expression was achieved at the same temperature
after 2 h which demonstrates the rapid expression capabilities of CFPS systems [179].
Interestingly, follow up studies expressing m-RI in BL21 Star DE3 E. coli extract that did not
express GroEL/ES were also effective in expressing m-RI at similar yields and expression trends
with the GSH/GSSG and DTT buffers (Figure 3-2).
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Figure 3-2: Soluble expression yields of m-RI at 15 °C (blue), 24 °C (green), and 30 °C (brown) after 2,
6, and 8 h reaction, expressed by BL21-Star (DE3) extract (normal extract). Different reduced conditions
are shown in solid (8 mM GSH/0.5 mM GSSG), pale (4 mM GSH/1 mM GSSG), diagonal stripes (12
mM DTT), horizontal stripes (4 mM DTT), and no color (Native) and at the same color according to
reaction temperature.

This suggests that the CFPS environment is more conducive to high soluble titers of m-RI
than the E. coli cytoplasm [164, 166] even without GroEL/ES overexpression, possibly because it
is more dilute by more than an order of magnitude [180]. Overall, the clear advantages of reducing
agents suggest that insoluble aggregates may result directly from incorrect intramolecular disulfide
bond formation, and that soluble conformations are preserved by the presence of reducing agents.
In anticipation that purification of the soluble m-RI is desirable, a 6xHis-tag was added to
either N or C-terminals of the insert m-RI gene by QuikChange II mutagenesis protocol and
insertions were confirmed by sequencing. m-RI did not express well after adding 6xHis-tag to the
N-terminal of m-RI (Figure B-1A). The soluble expression yield for the C-terminal 6xHis-tag
(expressed at 24 °C and 2 h by pOFX extract in presence or absence of 12 mM DTT) was
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comparable (75-80%) to the no tag m-RI (Figure B-1A). Full-length m-RI expression (with and
without 6xHis-tag) was confirmed using SDS-PAGE and autoradiography (Figure 3-3).

Figure 3-3: A) SDS-PAGE gel for m-RIs after staining with Coomassie blue (SimplyBlue, SafeStain,
Thermofisher scientific) and (B) the autoradiogram after 3 days exposure. The pre-stained protein
standard (10-250 kDa) is shown before the samples (P7712, NEB). Lanes 1, 2, and 3 are soluble m-RIs
expressed at 24 °C and 2 h in reduced, oxidized, and native CFPS conditions, respectively. Lane 4 is the
commercial m-RI (NEB, Ipswich, MA). Lanes 5 and 6 are m-RIs containing C-terminal 6xHis-tag
expressed at 24 °C and 2 h in native CFPS conditions before purification and after purification.
Autoradiograms show the right size (~50 kDa) of the in-house m-RI.

3.3.2

m-RI activity
The primary purpose of m-RI expression in this study is to provide a low-cost option for

supplying m-RI to CFPS biosensors that require m-RI for use with human body fluid samples.
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Figure 3-4: A) Schematic illustration of the CFPS reaction with RNase inhibition activity by adding CFPS
produced m-RI to a second CFPS reaction expressing sfGFP as the reporter protein. B) RNase inhibition
of three m-RI preparation freshly expressed at 15 °C-2h (blue), 15 °C-6h (yellow), and 24 °C-2 h (green)
with 3 ng/µl (solid colors), 2 ng/µl (diagonal stripes), and 1 ng/µl (horizontal stripes) soluble m-RI
concentrations. All m-RIs were expressed by CFPS in an extract with GroEL/ES overexpressed and
added directly without purification or freeze-thawing to a second CFPS reaction expressing sfGFP in the
presence of 30% human saliva. RNase inhibition activity of 1U/µl reaction of commercially obtained -mRI from NEB is shown in purple and a control sfGFP CFPS reaction without saliva or m-RI addition is
shown in grey. Near complete sfGFP production inhibition is demonstrated when 30% saliva is added to
the sfGFP-producing CFPS reaction without the addition of m-RI (red).
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The activity of soluble m-RI expressed at different conditions was thus assessed by adding
1-3 ng/µl soluble unpurified m-RI to a second CFPS reaction producing biosensor reporter protein
sfGFP in presence of 30% human saliva (Figure 3-4A). Saliva was selected as the target human
fluid as it contains different RNases (including RNase 1, RNase 3, and RNase H) at significant
concentrations [73] and contains biomarkers for diagnosis or treatment purposes. Most
importantly, saliva is easily collected in a non-invasive manner and does not require trained
personnel or special equipment for its collection, making it ideal for at-home testing [181].
The temperature and time CFPS conditions tested for m-RI activity were 24 °C for 2 h as
most m-RI synthesis at 24 °C was complete after 2 h (Figure 3-1) and 15 °C for 2 h and 6 h where
m-RI synthesis at 15 °C appeared complete after 6 h (Figure 3-1). The lower temperatures and
times were especially considered important due to previous in vivo reports where temperatures as
low as room temperature and shorter induction periods results in significant higher m-RI specific
activities [166]. While the temperature and time ranges were constricted, the original range of
GSH/GSSG and DTT redox buffers were maintained and Figure 3-4B reports sfGFP CFPS
expression in 30% saliva where unpurified CFPS-produced m-RI is provided as a reagent at 1, 2,
and 3 ng/µl (horizontal stripes, diagonal stripes, and solid colors, respectively). As a comparison,
sfGFP expression in absence of saliva and m-RI (grey bar), sfGFP expression in presence of 30%
saliva and 1 U/µl reaction of the commercial m-RI (NEB, Ipswich, MA, purple bar), and sfGFP
expression in presence of 30% saliva and absence of any RNase inhibitors (red bar) are included
in Figure 3-4B.
As expected, CFPS reaction in the presence of 30% saliva without m-RI resulted in
undetectable amounts of sfGFP protein (red bar, Figure 3-4B) and the addition of commercial mRI recovers most sfGFP expression (purple bar compared to grey bar, Figure 3-4B). Adding 3
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ng/µl of m-RI produced at 15 °C by CFPS (blue and yellow solid bars, Figure 3-4B) performed
equivalently or better at restoring sfGFP production in the presence of saliva as compared to 1U/µl
of commercial m-RI. When the concentration of CFPS-produced m-RI is reduced to 1 ng/µl, only
the m-RI produced at 15 °C for 2 h with 4 or 12 mM DTT or 8 mM GSH / 0.5 mM GSSG buffers
were effective at recovering all the sfGFP production capabilities. When comparing the data in
aggregate, 12 mM DTT appeared to be the best performing buffer (which also has most reducing
redox potential) for all m-RI-producing CFPS temperatures and time conditions tested. This result
of optimal CFPS expression of m-RI at 2 h, 15 °C and 12 mM DTT is consistent with the high
quantity of unpaired cysteines (30) in m-RI and previously reported in vivo expression trends
where lower temperature, strongly reducing redox conditions, and shortened expression windows
were most effective at producing active m-RI [166].
It should also be noted, that adding either C- or N-terminal 6xHis-tags to m-RI caused a
complete loss of activity (Figure B-1B), thus using unpurified m-RI is particularly important as
using a purified product would require not only purification steps but also cleavage of the tag
which would significantly increase its costs and justifies the higher costs of commercially available
purified m-RI.

3.3.3

Stability of m-RI
Producing m-RI with CFPS immediately before incorporation with CFPS biosensor

reagents is more cumbersome than stockpiling CFPS-produced m-RI as a frozen, ready-made
reagent when assembling CFPS biosensors. Thus, CFPS-produced and unpurified m-RI activity
was assessed after one and two freeze-thaw cycles as detailed in the Methods section. After freezethawing, m-RI activity was analyzed using the same procedure as described above (i.e., a second
46

CFPS reaction expressing sfGFP in the presence of 30% (v/v) saliva) and the result is reported in
Figure B-2 (after one freeze-thaw cycle) and in Figure 3-5 (after two freeze-thaw cycles).
After two freeze thaw cycles it is abundantly clear that m-RI expressed at 15 °C for 2 h is
much more active than m-RI expressed at 24 °C or 15 °C after 6 h where m-RI expressed at these
conditions did not restore sfGFP expression (Figure 3-5). Also 12 mM DTT was confirmed as the
best buffer for both active and stable m-RI expression.
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Figure 3-5: m-RI activity after two freeze-thaw cycles. m-RIs expressed at 15 °C- 2h (blue), 15 °C- 6h
(yellow), and 24 °C- 2 h (green) with 3 ng/µl (solid colors), 2 ng/µl (diagonal stripes), and 1 ng/µl
(horizontal stripes) soluble m-RI concentrations. All m-RIs were expressed by pOFX extract. RNase
inhibition activity of NEB-m-RI is shown in purple and the No saliva/m-RI control is in grey.

Most importantly, this result verifies that simply adding 2 ng/µl of CFPS-produced m-RI
at 15 °C, 2 h, and 12 mM DTT is sufficient to account for m-RI activity losses due to freeze
thawing and completely restore CFPS activity in the 30% human saliva samples tested.
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Accordingly, m-RI was expressed at 15 °C for 2 h in presence of 12 mM DTT and added to 50 µl
CFPS reactions (with 6 ng/µl final concentration) to inhibit RNase activity in varied amounts of
three human fluids of saliva, serum, and urine (section 3.3.4) or as a saliva-based glutamine
biosensor (section 3.3.5).
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Figure 3-6: m-RI activity after one freeze-thaw cycle. m-RIs expressed by pOFX extract (blue) or the
normal extract (green) with 3 ng/µl (solid colors), 2 ng/µl (diagonal stripes), and 1 ng/µl (horizontal
stripes) soluble m-RI concentrations. All m-RIs were expressed at 15 °C and 2 h. RNase inhibition
activity of NEB-m-RI is shown in purple and the No saliva/m-RI control is in grey.

In all activity and stability data presented so far, m-RI was expressed using an E. coli
extract that was enriched for GroEL/ES (pOFX plasmid overexpresses GroEL/ES during
fermentation of E. coli used to produce extract). However, previously mentioned m-RI expression
data suggested similar yields of soluble m-RI could be obtained in the same E. coli lysate without
GroEL/ES enrichment (without pOFX, Figure 3-2). The activity of m-RI expressed at 15 °C and
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2 h (highest activity and stability condition) in both extracts were assessed for activity after one
freeze thaw cycle (Figure 3-6). m-RI expressed in extract with overexpressed levels of GroEL/ES
had higher activity, justifying the use of this extract condition and agrees with prior in vivo m-RI
expression results [164, 166].

3.3.4

CFPS-produced m-RI restores CFPS production in samples containing up to 100%
human body fluids of saliva and serum and up to 40% urine
To demonstrate the utility of CFPS-produced m-RI beyond 30% saliva samples, the impact

of different concentrations of human serum, urine, and saliva samples on CFPS reactions
producing sfGFP as the reporter were assessed (Figure 3-7A). Simply adding these fluids to CFPS
at concentrations as low as 0.5% (v/v) had a statistically significant negative impact on CFPS. At
8% (v/v) of these samples, greater than 95% of the CFPS production capability was lost (Figure
3-7A). However, in-house, CFPS m-RI added to the sfGFP-producing reaction effectively
inhibited sample RNases sufficient to restore most of the sfGFP production capability. (Figure 37B-D).
A “just add sample” biosensor format is advantageous in point-of-care applications but
requires CFPS to retain activity in 100% (v/v) human sample fluid. To test m-RI performance in
CFPS with human fluid volume percent up to 100%, the sfGFP-producing CFPS reaction was
lyophilized after unpurified m-RI was added to it. Lyophilization has been reported as an excellent
way to facilitate long-term shelf-stable storage and on-demand use of CFPS biosensors [64, 154]
and these results also demonstrate the ability of CFPS-produced m-RI to be included in this format.
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Figure 3-7: A) Relative sfGFP expression capability in presence of three human fluids of saliva (blue),
urine (green), and serum (orange) in absence of any RNase inhibitors. sfGFP expression in presence of
0.05-12 volume percent human fluids are normalized relative to the reaction without human fluid (grey,
100%). All reactions were performed at 37 ℃, 3 h and error bars represent one standard deviation for n=3
reactions. B) Relative sfGFP expression of the rehydrated CFPS reactions by (10-100) vol% of saliva
(blue), serum (orange), and urine (green) supplemented with 1 ng/µl freshly prepared in-house m-RI. C)
Relative sfGFP expression of the rehydrated CFPS reactions by (10-100) vol% of saliva (blue), serum
(orange), and urine (green) supplemented with 6 ng/µl freshly prepared in-house m-RI. D) Relative sfGFP
expression of the rehydrated CFPS reactions by (10-100) vol% human fluids of saliva (blue), serum
(orange), and urine (green) supplemented with 15 ng/µl of freshly prepared in-house m-RI. m-RIs were
expressed at 15 ℃ for 2 h, in presence of 12 mM DTT and GroEL/ES chaperones. All sfGFP expression
yields are normalized relative to the control (water) CFPS reaction at the indicated m-RI concentration.

As shown in Figure 3-7B, 1 ng/µl of CFPS-produced m-RI (freshly expressed at 15 °C, 2
h, in presence of 12 mM DTT) was sufficient to restore most CFPS activity in up to 40% saliva
and 10% urine. Increasing the m-RI concentration to 6 ng/µl improved the recovery of CFPS
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activity at even higher percentages of human samples and appears to be sufficient to recover most
of the CFPS activity with 100% saliva (Figure 3-7C). At 15 ng/µl, ~80% of CFPS activity was
recovered when the lyophilized reagents were rehydrated with 100% saliva, ~25% of CFPS
activity was recovered in 100% serum samples, and ~50% of CFPS activity was recovered in 30%
urine (Figure 3-7D). While inhibitory effects beyond RNases likely exist in these samples, it
appears that RNase inhibitor is a primary limiting factor, and m-RI is effective in restoring CFPS
activity in these samples, potentially enabling detection of myriad biomarkers in these fluids using
CFPS biosensors.

3.3.5

CFPS-produced m-RI enables glutamine CFPS-biosensor application in human
saliva
To further demonstrate the utility of CFPS-produced m-RI with on-demand CFPS

biosensors using human fluids, a recently reported CFPS-glutamine biosensor was tested [97].
Previously, this biosensor required commercial m-RI (NEB) and compatibility with lyophilization
or with human saliva samples has not been demonstrated. As the most abundant amino acid,
glutamine is an important biomarker for variety of diseases or disorders including diabetes, cancer,
kidney disease, chronic intestinal pseudo-obstruction, brain dysfunction, and Alzheimer’s disease
[103, 169, 170]. Determining glutamine concentration with saliva is less invasive and has been
postulated as a better alternative to blood or serum for infants, disabled people, or people with
hemophilia [182].
CFPS-based glutamine biosensing works by omitting glutamine as a CFPS reagent and
inhibiting endogenous E. coli glutamine synthetase activity in the cell lysate with MSO [97]. The
absence of glutamine in a test sample results in undetectable levels of full-length fluorescent sfGFP
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synthesis, while the concentration of full-length sfGFP is proportional to the amount of glutamine
in the sample. Indeed, linear correlation between glutamine concentrations and sfGFP production
has been reported over the physiological range of glutamine concentrations in the body [97].
To demonstrate the utility of in-house m-RI for CFPS biosensing in human fluids, the
CFPS-glutamine biosensor was constructed as reported previously [97], with two exceptions 1) 6
ng/µl CFPS-produced m-RI (freshly expressed at 15 °C, 2 h, in presence of 12 mM DTT) replaced
commercial m-RI and 2) all CFPS-reagents were lyophilized together to create a “just-add-sample”
single-pot batch biosensor. 40% (v/v) human saliva and water was spiked with increasing
concentrations of glutamine and used to rehydrate the lyophilized CFPS glutamine biosensor
(Figure 3-8A). Additionally, the performance of the lyophilized glutamine biosensor in the
presence of higher concentrations of saliva was assessed (Figure 3-8B).
As is shown in Figure 3-8A, a strong linear correlation (R2 > 0.98) between the concentration of
glutamine added to a control water sample (gray) and the saliva sample (blue) were observed with
similar slopes and the higher sfGFP results for saliva samples relative to water samples are
expected due to glutamine levels naturally in saliva samples (x-axis reports glutamine added to
these samples).
To further verify glutamine detection, saliva was added at increasing volume percentages
(20%, 40%, and 70%) to the lyophilized CFPS biosensor (Figure 3-8B), which increases the
overall effective concentration of glutamine in the biosensor with the glutamine naturally in saliva
[183]. A strong linear correlation between sfGFP-production in the glutamine-depleted CFPS
biosensor to the saliva concentration was observed.
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Figure 3-8: A) Lyophilized glutamine biosensor CFPS reactions containing 6 ng/µl m-RI (expressed at 15
°C, 2 h with 12 mM DTT) rehydrated with water (grey dots/line) or 40% (v/v) saliva (blue dots/line).
Rehydration samples were spiked with glutamine to achieve indicated CFPS glutamine concentrations.
B) Lyophilized glutamine biosensor CFPS reactions containing 6 ng/µl m-RI (expressed at 15 °C, 2 h
with 12 mM DTT) rehydrated with 0%, 20%, 40%, and 70% (v/v) saliva (blue dots/line).

The range of 20-70% saliva was selected as sfGFP production with 6 ng/µl m-RI used in
the test was essentially constant in sfGFP-producing CFPS reactions that were not initiated without
glutamine (Figure 3-7B blue bars). Thus, CFPS-produced m-RI enables detection of glutamine in
human saliva as a lyophilized ”just-add-sample” biosensor. Importantly, in-house m-RI added
directly to the CFPS glutamine biosensor decreases the overall reagent cost of the sensor by ~90%
(Appendix B) as it provides m-RI without expensive purification or other post-translational
processing. It is important to note that this estimated reagent cost does not include labor,
equipment, and m-RI activity validation, however, these costs would decrease significantly with
scale-up [184].
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0.8

3.4

Conclusion
Analysis of human fluids often requires significant sample volumes (≥ 1 mL), labeling,

freezing/cooling, and transportation to the lab before analysis [182]. These cumbersome
requirements highlight the need for point-of-care, “just-add-sample” biosensors. This study
leverages the flexible nature of CFPS systems to optimize the production of highly soluble and
active m-RIs. Reaction temperature, reaction time, reducing potential, and presence of chaperones
were manipulated to achieve soluble m-RI titers of nearly 1 g/L. Among the expression conditions
tested, 24 °C and 6 h in presence of 12 mM DTT and GroEL/ES folding chaperones produced the
highest soluble yield. However, m-RI with the highest specific activity and stability after freezethawing was produced in CFPS reactions at 15 °C for 2 h in the presence of 12 mM DTT and
GroEL/ES folding chaperones (Figure 3-4B and Figure 3-5). The concentrations of CFPSproduced m-RI required to inhibit the RNases native in human body samples of blood, urine, and
saliva, and enable the production CFPS-based biosensor reporters, was also determined (Figure 37). CFPS-produced m-RI lyophilized with CFPS reagents enabled CFPS biosensor reporter
production in the presence of 100 volume percent human samples. Finally, a CFPS-based
glutamine biosensor was created for the first time that 1) accepts saliva as the test sample and 2)
is lyophilized in a “just-add-sample” format for on-demand at-home use, and 3) employs CFPSproduced m-RI rather than commercial m-RI to inhibit RNases, thus reducing the total reagent cost
of the glutamine biosensor by ~90%. This work demonstrates that m-RI produced with CFPS has
the potential to enable CFPS biomarker detection in human serum, urine, and saliva, thus
improving diagnosis and treatment of many debilitating disorders and diseases.
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4

STREAMLINING CFPS BIOSENSORS FOR USE IN HUMAN FLUIDS: IN SITU
RNASE INHIBITOR PRODUCTION DURING EXTRACT PREPARATION

This chapter is an adaptation from an accepted manuscript in Biochemical Engineering
Journal by Mehran Soltani and Bradley Bundy entitled “Streamlining Cell-Free Protein Synthesis
Biosensors for use in Human Fluids: in situ RNase Inhibitor Production During Extract
Preparation” (https://doi.org/10.1016/j.bej.2021.108158). The authors presented a streamlined
method to prepare E. coli extract with RNase inhibition activity and tested the best-performing
extract in three human fluids.

4.1

Introduction
A key obstacle preventing widespread application of CFPS biosensors in human body fluids

is the presence of RNases [73] which degrade mRNA and tRNA and thus prevent reporter protein
expression [74]. Addition of RNase inhibitors to a CFPS system alleviates this issue, but the
commercial form of this reagent accounts for ~90% cost of an in-house E. coli-lysate-based CFPS
[185] which limits low-cost applications of CFPS biosensors. Here we present the engineering of
E. coli extracts with RNase inhibition activities sufficient to enable CFPS in three human body
fluids (saliva, serum, and urine).
CFPS is an open-access platform for fast, high-yield, and flexible production of a variety of
products [31, 44, 186]. CFPS platforms are based either on clarified cell lysates or the assembly
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of individually purified transcription, translation, and protein folding machineries (e.g. PURE
system [187]). CFPS-based biosensors thus do not have cell-viability or membrane transport
limitations of cell-based biosensors [80, 188]. However, CFPS-biosensors can be expensive. For
example the PURE system is ~10-30 times more expensive than the clarified lysate system [189]
and systems based on insect, mammalian, or plant cells are typically more expensive and less
robust than E. coli-lysate-based systems [25, 189, 190].
Importantly, E. coli-lysate-based CFPS systems have been engineered for single-pot
lyophilization which facilitates distributed, on-demand, point-of-care application as biosensors
[88, 89, 154, 191]. Finally, E. coli-lysate-based CFPS biosensors have been engineered for many
human health related applications, including the detection of viruses (Zika and Ebola) [63, 90],
water contaminants [91-93], endocrine-disrupting chemicals [60, 61, 74], biomarkers of infectious
diseases [94, 95], and metabolites [62, 96, 97, 192].
Currently, the main cost of using E. coli-lysate-based CFPS biosensors in human fluids is
the inclusion of commercial RNase inhibitors, specifically murine RNase Inhibitor or m-RI, to
counteract RNases naturally present in human fluids. Thus, there is motivation to express m-RI in
E. coli during fermentation prior to lysis and use in CFPS. However, expressing m-RI has been
challenging because of its hydrophobic core and high number of unbound cysteines [100]. Thus,
the production of inactive m-RI due to aggregation and misfolding is commonplace [99, 100].
Previously, Sirkus et al. reported improved soluble yields and activity of m-RI with an in vivo
E.coli-based system by tuning several factors including adding different fusion partners to the Nterminus of m-RI, using different redox buffers to the medium composition, applying different
growth temperatures, and changing the ribosome binding site strength [164-166]. They reported
6xHis-Maltose Binding Protein (MBP) fusion partner as the suitable fusion partner for the highest
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solubility (425 µg/mL) regardless of growth temperature or ribosome binding site strength [165].
However, the fusion partner decreases m-RI activity and needs to be removed from m-RI postexpression [165]. Later, improved cytoplasmic expression of active m-RI in E. coli was achieved
by slow synthesis and folding via low post-induction temperature (22 °C) and the addition of DTT
to shift the redox potential in the media [164, 166]. It was hypothesized that lower slower synthesis
rates and a more reduced redox-potential preventing disulfide bond formation encouraged proper
folding of the expressed m-RI [166].
In this study the suitable condition for making extract with overexpressed and active m-RI
(m-RI extract) will be considered by changing growth temperature, co-expression of GroEL/ES
folding chaperones in extracts, and addition of reducing buffers such as DTT to E. coli cultures.
Lyophilized CFPS reactions containing m-RI extracts were used with 0-100% of three human body
fluids of saliva, serum, and urine to determine the compatibility and applicability of m-RI extracts
with lyophilization and on-demand utilization with popular human fluids in diagnosis or
monitoring of diseases [101, 102].
Finally, m-RI extract applicability is demonstrated with a glutamine biosensor in 30%
human saliva. The glutamine biosensor has been developed recently [97] and glutamine is an
important biomarker for a variety of disorders and diseases as mentioned previously in Chapter 3
[103, 104]. As a side result, CFPS is directly compared against a commercial RNase activity kit as
a cost-effective method to assess RNase activity (~$0.14 compared to ~$10 using RNase AlertTM
Lab Test Kit, ThermoFisher, Waltham, MA).
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4.2
4.2.1

Materials and methods
Extract preparation
The m-RI sequence was obtained from Protein Data Bank (PDB ID: 3TSR), codon

optimized for expression in E. coli, and constructed by Twist Bioscience (San Franscisco, CA) in
a high copy number pTwist construct with Ampicillin as the antibiotic resistance marker. pTwist
m-RI gene was chemically transformed in BL21-Star (DE3) (Invitrogen, Carlsbad, CA) competent
cells harboring no additional plasmids (m-RI/Normal extract) or with previously chemically
transformed GroEL/ES plasmid (m-RI + pOFX extract, a kind gift from D.M. Kim). E. coli cell
extracts were prepared as described previously [26, 122] with some modifications to enable higher
RNase inhibition activities. 5 ml LB media containing Ampicillin (for m-RI extract) or Ampicillin
and Spectinomycin (for m-RI + pOFX extract) in glass cell culture tubes were inoculated and
grown overnight at 37 °C, 280 RPM. The cells then were added to 100 ml 2xYT media (16 g/L
tryptone, 10 g/L yeast-extract, 5 g/L sodium chloride) in baffled 500 ml flasks and incubated at 37
°C, 280 RPM for ~ 5 h. After reaching to an OD600 of ~2.0, the cell cultures were added to 900 ml
fresh 2xYT media in a 2.5 L Tunair baffled shake flask (IBI scientific, IA) and transferred to
another shaker incubator at 15-37 °C. At an OD600 of 0.5-0.6, the cells were induced with 1 ml of
1 M isopropyl β-D-1-thiogalactopyranoside (IPTG). The cell cultures were continued without DTT
addition (No DTT), supplemented with DTT (12 mM final concentration) at the point of induction
(simultaneous DTT/IPTG), or supplemented with DTT (12 mM final concentration) at an OD600
of ~0.9 (delayed DTT). All cell cultures were harvested toward the end of logarithmic phase
(OD600 between 1.2 and 3.5 depending on culture temperature and DTT content) and centrifuged
at 8,000 RCF for 20 min at 4 °C. The cells were then washed with 10 ml cold buffer A per gram
wet cells and centrifuged again at 8,000 RCF for 20 min at 4 °C. Buffer A contains 60 mM
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Potassium Glutamate, 10 mM Tris, 14 mM Magnesium Acetate, and 1 mM DTT (final pH adjusted
to 8.2) and autoclaved before use. Cells were resuspended again in 0.7 ml chilled buffer A per
gram wet cells and were lysed by passing three times through a French press homogenizer
(Avestin, Ottawa, Canada) at 21,000 PSI with cooling intervals to avoid extract overheating.
Finally, the cell debris were separated from the cell extract (top portion) by centrifugation at 12,000
RCF for 30 min at 4 °C and the supernatant was carefully pipetted out and aliquoted to 100-300
µl volumes, flash-frozen by liquid nitrogen, and kept at -80 °C until single-use in CFPS reactions.

4.2.2

CFPS
Coupled transcription/translation CFPS reactions were carried out in 50 µl reaction

volumes in 2 ml microcentrifuge tubes (GeneMate, BioExpress) at 37 °C, 280 RPM for 3 h unless
otherwise noted with PANOx-SP system to energize the reactions as described previously [16,
193]. All CFPS reactions contained 25% (v/v) E. coli extract, 25% (v/v) small molecules master
mix, 16 mM magnesium glutamate, 2 nM PY71- sfGFP DNA plasmid, and deionized water for
the remaining 50 µl reaction. As reported previously [26], small molecules master mix contains 1
mM 1,4-diaminobutane, 40 mM phosphoenolpyruvate (PEP), 175 mM potassium glutamate, 2.7
mM potassium oxalate, 1.5 mM spermidine, 10 mM ammonium glutamate, 0.33 mM nicotinamide
adenine dinucleotide (NAD), 0.27 mM coenzyme A (CoA), 1.2 mM ATP, 0.86 mM CTP, 0.86
mM GTP, 0.86 mM UTP, 0.17 mM folinic acid, and 2 mM of all the natural amino acids except
glutamic acid which was added separately as magnesium glutamate. All chemicals were obtained
from Cayman Chemical Company (Ann Arbor, MI) unless otherwise noted. The PY71 sfGFP
plasmid was designed and constructed as described previously [16]. It was transformed in XL1Blue chemical competent cells (Agilent Technologies, Santa Clara, CA). To prepare DNA
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plasmid, the cells were grown in 200 ml TB media (24 g/L yest extract, 12 g/L tryptone, and 4
ml/L glycerol) at 37 °C, 280 RPM overnight. QIAGEN Plasmid Maxi Kit (Valencia, CA) was
used to isolate the plasmid according to the manufacturer’s instructions. For CFPS reactions
supplemented with externally added T7 RNA polymerase, 1% (v/v) T7 RNA polymerase (from
HiScribe T7 High Yield RNA Synthetase Kit, NEB, Ipswich, MA) was added to CFPS reactions
with the same composition and reaction condition as mentioned earlier. sfGFP expression yields
in CFPS reactions were quantified by fluorescent reading. 20 µl of CFPS was mixed with 45 µl
deionized water in a well of a Costar® black 96-well plate (Corning Inc., Corning, NY) and
fluorescence was measured at 480/510 nm excitation/emission by a BioTek Synergy MX
microplate reader (Biotek Instruments, Winooski, VT). sfGFP yields were reported in relative
fluorescence units (RFU), or normalized sfGFP expression relative to a specified reference
reaction, or as µg/ml (determined by converting RFU to concentration determined by C14radiolabeled sfGFP as described previously [4]).
NuPAGE 10% Bis-Tris Gel (Invitrogen, Carlsbad, CA) in reducing condition was used to
visualize the expressed proteins in extracts according to manufacturer’s instructions with minor
modifications. Commercial m-RI (NEB, Ipswich, MA) was used as a control for m-RI and Color
Prestained Protein Standard, broad range (NEB- Cat.# P7719S, Ipswich, MA) was used as the
standard protein marker. All E. coli cells were grown at 24 °C post-induction and cell-extracts
were prepared as described previously. Following extract preparation, each cell-lysate before or
after centrifugation was ran on a protein gel after 50x dilution. Coomassie SimplyBlueTM
SafeStain (Invitrogen, Carlsbad, CA) was used for visualizing protein bands.
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4.2.3

Assessment of the RNase inhibition activity of m-RI extracts
RNase AlertTM Lab Test Kit (Cat. #: AM1964, ThermoFisher Scientific, Waltham, MA)

was used per manufacturer’s instructions to test total RNase activity of CFPS reaction and three
human body fluids of saliva, serum, and urine (n=3). According to the manufacturer, the assay is
based on a modified RNA oligonucleotide substrate which emits a fluorescent signal detectable at
490/520 nm (excitation/emission) upon cleavage by a variety of RNases including RNase A,
RNase T1, RNase I, micrococcal nuclease, and S1 nucleases. Standard RNase A (0.01 U/ml) is
supplied with this kit and was used for a calibration curve and to report total RNase activity of
samples as equivalent RNase A activity per liter tested sample (Unit equivalent RNase A/L).
As an alternative to the commercial RNase activity kit and to significantly reduce the assay
cost, CFPS-producing sfGFP was used to determine m-RI activity against RNase A (10 mg/ml
stock concentration, supplied with QIAGEN Plasmid Maxi Kit (Valencia, CA)) as the source of
externally added RNase to the systems with the final concentrations of up to 400 ng/ml RNase A
in CFPS reactions. CFPS reactions were assembled as explained before with some modifications.
25% (v/v) extract was used in all CFPS reactions (50 µl reaction volume) of which 30% (3.75 µl),
50% (6.25 µl), or 70% (8.75 µl) was m-RI extract and balanced to a total of 25% extract (12.5 µl
in a 50 µl reaction) with a regular BL21-Star (DE3) extract. sfGFP expression after 3 h at 37 °C
were measured by fluorescent reading as discussed before and normalized to sfGFP expression by
the CFPS reaction with no externally added RNase A.
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4.2.4

RNase Inhibition activity of m-RI extracts in lyophilized CFPS reactions against three
human body fluids
The RNase inhibition activities of the two best-performing m-RI extracts against 0-100%

(v/v) of three human body fluids of saliva, serum, and urine were assessed. CFPS reactions (50 µl
reactions) with 25% (v/v) total extract were assembled as described previously with 12.5% (v/v)
m-RI extract (6.25 µl in each reaction), and 12.5% (v/v) regular BL21-Star (DE3) extract (50% of
each extract). All reactions were assembled on ice in 2 ml microcentrifuge tubes and immediately
were flash-frozen in liquid nitrogen and lyophilized by a freeze-dryer (Labconco FreeZone 2.5L,
Kansas City, MO) at -50 °C and <90 mTorr for at least 15 h. All lyophilized reactions were
rehydrated with 0-100% (v/v) of human body fluids (balanced to 50 µl final volume by deionized
water) after at least one-week storage of the lyophilized CFPS reactions at -20 °C freezer. Saliva
and urine samples were obtained from volunteers (following IRB approved protocols) and the
human serum was obtained from Gemini Bio Products (Sacramento, CA). All human body fluids
were aliquoted in 100 or 400 µl volumes, flash-frozen, and stored at -80 °C until thawing on ice
before single-use.

4.2.5

Glutamine biosensor
Glutamine biosensor was tested as a proof-of-concept to show applicability of the developed

m-RI extract with a human body fluid (saliva) in a biosensor application. The glutamine biosensor
was based on a recently published study [97] which used serum as the human body fluids and a
commercial RNase inhibitor without investigating on-demand applicability of such a platform.
CFPS reaction assembled like what described earlier except that glutamine was eliminated from
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the small molecules master mix to enable its detection. Additionally, because of native glutamine
synthesis capability of E. coli extract (by glutamine synthetase), methionine sulfoximine (MSO)
was added (70 mM final concentration in a CFPS reaction) to the reaction to inhibit innate native
glutamine synthesis pathway in E. coli extract as has been explained previously [97]. Rehydrated
samples (with 30% saliva or deionized water as the control) were supplemented with 0 to 200 µM
final concentration of externally added glutamine in CFPS before incubation at 37 °C for 3 h (n≥3).
All sfGFP expressions yields were normalized by subtracting expression in CFPS reactions with
no externally added glutamine (background expression of sfGFP).

4.3

4.3.1

Results and discussion

Quantifying the impact of RNase addition on CFPS protein yields
The motivation for this work is to mitigate the loss of CFPS protein expression capability

when RNases are added, which is a common problem for CFPS biosensing in human body fluids.
To better understand and quantify this impact, increasing amounts of RNase A (QIAGEN,
Valencia, CA) were added to CFPS reactions up to a final concentration of 100 ng/ml RNase A.
As shown in Figure 4-1, sfGFP-producing CFPS reaction could tolerate up to ~10 ng/ml added
RNase A in addition to the native E. coli RNases [194] carried over in the clarified CFPS extract.
However, the CFPS protein production dropped significantly (more than 85% reduction) at a
concentration of 20 ng/ml added RNase A and was undetectable at a concentration of 60 ng/ml
added RNase A.
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Figure 4-1: Relative sfGFP expression in regular CFPS reactions without RNase inhibition activity and in
the presence of up to 100 ng/ml spiked RNase A. Error bars represent one standard deviation for n ≥ 3.

4.3.2

Overexpression of m-RI in E. coli extract and RNase inhibition activity
The open nature of CFPS systems allows the direct addition of small molecules, nucleic

acid, and proteins (such as RNase Inhibitor) as desired. However, a lower cost alternative to adding
individually purified enzymes or chaperones is to induce their expression in the E. coli
fermentation that eventually becomes the E. coli extract used for CFPS [24]. This approach has
been successfully applied for supplying T7RNA polymerase [81, 82], DsbC disulfide bond
isomerase [83, 84], GroEL/ES folding chaperones [84, 85], and orthogonal machineries of
tRNA/aminoacyl-tRNA synthetase needed for unnatural amino acid incorporation [4, 16, 50, 87].
However, there is no report of producing CFPS extract with RNase inhibitors. RNase inhibitors
are necessary for CFPS biosensors to function in human body fluids and the commercially
available form of this reagent needed (Murine RNase Inhibitor, NEB- Cat.# M0314S, Ipswich,
MA) costs ~9 times more than the combined cost of other E. coli-lysate based CFPS reagents
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[185]. We recently reported m-RI production in CFPS reactions and its potential to provide the
needed m-RI in a second biosensing CFPS reaction in human fluids which reduces the m-RI cost
[185]. However, including m-RI production as part of the extract preparation procedure would
eliminate this extra step and streamline CFPS biosensor use in human fluids while also reducing
the m-RI cost.
Toward this end, m-RI was cloned into a pTwist plasmid as described in the methods and
expressed in with E. coli BL21-Star (DE3) during fermentation used to produce CFPS extract.
Previous results reported lower fermentation temperatures, addition of DTT to fermentation media,
and overexpression of protein folding chaperoned improved the activity of m-RI when expressed
in E .coli [164-166].
Initial attempts expressing m-RI during the cell extract preparation fermentation were thus
performed at both 37 °C or 24 °C and in presence or absence of 12 mM DTT. However, this
resulted in extract with undetectable m-RI activity (Figure 4-2). Therefore, GroEL/ES were
coexpressed with m-RI during the E. coli BL21-Star (DE3) fermentation used to produce CFPS
extract as detailed in the methods (m-RI + pOFX). In addition, the fermentation temperatures were
lowered to 24 °C and 15 °C for slower synthesis and proper folding of nascent proteins [173, 174].
Also, due to the 30 cysteines in m-RI that must remain in a reduced form for proper m-RI
activity the effect of adding 12 mM DTT to the fermentation media at the time induction
(simultaneous DTT/IPTG) or post induction at OD600 of ~0.9 (delayed DTT) was also assessed.
As expected [195], fermentation at 15 °C compared to 24 °C resulted in slower growth kinetics
and a ~50% reduction in cell densities at harvest (Figure 4-3).
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Figure 4-2: sfGFP expression of CFPS reactions containing regular BL21-Star (DE3) extract grown at 37
°C (orange bars, horizontal stripes) and m-RI in BL21-Star (DE3) extracts (m-RI, normal extracts) grown
at 24 °C in presence of 12 mM final concentration of DTT (blue bars) or absence of DTT (green bars).
RNase inhibition activity of all extracts were determined by adding 100 ng/ml RNase A to CFPS
reactions. Error bars represent one standard of deviation, n≥2. It is important to note that none of the
fermentations used to prepare these extracts were engineered for coexpression of folding chaperones
GroEL/ES.
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Figure 4-3: Growth curves (OD600) for m-RI + pOFX extracts grown at 24 °C (Left) and 15 °C (Right).
Cells were grown in absence of DTT (blue points) or in presence of DTT (12 mM final concentration)
added at the point of induction (red points), or in presence of DTT (12 mM final concentration) added at
OD600 of ~0.9, post induction (green points).
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Additionally, the cells grew slower in presence of DTT. While these conditions are reported
as optimal for m-RI expression [164, 166], they are not optimal for producing E. coli extract for
CFPS and the resulting extracts had reduced CFPS protein production capabilities (Figure 4-4).
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Figure 4-4: sfGFP expression by CFPS using the extracts of m-RI + pOFX extract grown at 15 °C (solid
blue bars) or at 24 °C (diagonal orange bars) or normal BL21-Star (DE3) extract (horizontal green bar for
the extract grown at 37 °C and solid green bar for the extract grown at 15 °C). All CFPS reactions were
performed at 37 °C for 3 h. Error bars represent one standard deviation for n≥2.

This result is expected as E. coli has lower concentrations of the enzymes and cofactors
during periods of slower growth [196] and thus their concentration is expected to be lower in the
resulting extract. In addition, lower levels of T7 RNA polymerase (essential for transcription in
CFPS) is expected in these extracts, as GroEL, GroES, and m-RI are coexpressed with T7-RNA
polymerase and thus reduce the resources available for T7-RNA polymerase expression.
This is confirmed by improved CFPS yields when additional purified T7-RNA polymerase
(1% (v/v), HiScribe™ Kit, NEB, Ipswich, MA) was added to these extracts (Figure 4-5). Based

67

on these results it was hypothesized that extract with m-RI could be combined with extracts that
do not contain m-RI and were prepared using optimized extract preparation conditions (BL21-Star
(DE3) grown at 37 °C, no DTT added, no GroEL/ES, no m-RI; hereafter referred to as “regular
extract”) to achieve both significant CFPS production yields and RNase inhibition activity.
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Figure 4-5: sfGFP expression of regular CFPS reactions (no externally added RNase A) by m-RI + pOFX
extract (diagonal orange bars, grown at 24 °C, with GroEL/ES chaperones, No DTT) or regular BL21Star (DE3) extract (horizontal green bar for the extract in 37°C). CFPS reactions were supplemented with
0 or 1% (v/v) pure T7 RNA polymerase (NEB, Ipswich, MA). All CFPS reactions were performed at 37
°C for 3 h. Error bars represent one standard deviation for n≥2.

Initial experiments testing different extract combination ratios (varying percentage of mRI extract and regular extract) suggest that at least 30% regular extract and at least 30% m-RI
extract is needed for both significant CFPS production yields and RNase inhibition (Figure 4-6).
Thus, m-RI extract prepared with the above-described range of conditions for preparing
extract containing m-RI (24oC or 15oC; no DTT, delayed 12 mM DTT addition, 12 mM DTT
addition at induction; coexpression of GroEL/ES) were combined with regular extract at ratios of
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0/100, 30/70, 50/50, and 70/30 and assessed for CFPS production capabilities in the presence of
increasing concentrations of added RNase A (see Figure 4-7A).
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Figure 4-6: sfGFP expression by CFPS in the absence (blue bars) or presence (orange bars) of 30% saliva.
The extracts used for CFPS varied by the percentage of m-RI + pOFX extracts (10-70% (v/v), grown at
15 °C with No DTT added) combined with regular BL21-Star (DE3) extract. Error bars represent one
standard deviation from n ≥2.

RNase A was used instead of a human body fluid to eliminate the variability which can
exists from person to person and during different times of a day for each person [197]. A key result
from this study (Figure 4-7) is that m-RI extract prepared by E. coli fermentation at 24oC, without
DTT addition, and with GroEL/ES co-expression were the best for retaining high CFPS production
capability in the presence of 400 ng/ml RNase A in m-RI/regular extract combinations (Figure 47B).
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Figure 4-7: A) Schematic illustration of combining regular BL21-Star (DE3) extract (no RNase inhibition
activity) and m-RI + pOFX extract grown at 15 °C or 24 °C. Black (for m-RI+ pOFX extract) and dashedred arrows (for the regular BL21-Star extract) are drawn proportional to the amount of each extract
combined reaching final volumetric percentages of 0, 30, 50, 70 of m-RI + pOFX extract, from left to
right. B-G) CFPS activity of different combinations of regular and m-RI + pOFX extracts (30% in blue,
50% in orange, and 70% in grey) grown at 24 °C (B-D) or 15 °C (E-G) with up to 400 ng/ml RNase A
added. m-RI + pOFX extracts were fermented in the absence of DTT (B and E), in presence of 12 mM
DTT added simultaneously to the culture at IPTG induction (C and F), or in presence of 12 mM DTT
added at the post-induction OD600 of ~0.9 (D and G). Control CFPS reactions with the commercial m-RI
(1 U/µl NEB) were specified by purple. Control CFPS reaction with no added RNase A or m-RI + pOFX
extract included are specified in green and were used to normalized sfGFP expression yields of all
reactions. Error bars represent one standard deviation for n ≥ 3.

It is notable that the other conditions tested for m-RI extract preparation (15 °C, DTT
addition at different times) were also effective in retaining substantial CFPS production even in
the presence of high concentrations of RNase A (Figure 4-7C-G). Indeed, the most important factor
appears to be coexpression of GroEL/ES as no RNase inhibiting activity was observed in m-RI
containing extracts fermented without GroEL/ES (Figure 4-2). Furthermore, while sufficient
RNase inhibition activity for many applications in GroEL/ES-containing extracts is shown in
Figure 2, SDS-PAGE analysis revealed that a portion of m-RI produced during fermentation is
insoluble and thus not part of the final extract used for CFPS (Figure B-3 ). This suggests that
beyond the scope of the work presented herein even higher extract RNase inhibition activity could
be obtained in future optimization studies.
Finally, based on Figure 4-7, the 50/50 ratio of m-RI extract to regular extract seemed to
be the ideal ratio for retained CFPS activity in the presence of varying RNase A concentrations for
most conditions tested. Thus a 50/50 ratio extract combination of m-RI/regular extract was used
for subsequence studies with human body fluids where the m-RI extract is prepared at 24 °C with
GroEL/ES coexpression but without DTT addition. This condition has the highest RNase
inhibition activity compared to other conditions and it is the most convenient (e.g. room
temperature fermentation without DTT addition).
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4.3.3

RNase inhibition activity of m-RI + pOFX extract in CFPS reactions with up to 100%
human fluids
Figure 4-8A reports the retained CFPS activity of the optimal 50/50 m-RI/regular extract

combination described above in the presence of human saliva, serum, and urine. For this study,
CFPS reagents were lyophilized in a single pot [172, 191] and resolubilized in concentrations of
the three different human samples that ranged from 0 to 100% (v/v).
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Figure 4-8: A) sfGFP expression yields for lyophilized CFPS reagents rehydrated with 10-100% (v/v)
human body fluids of saliva (blue bars), serum (orange bars), or urine (green bars). Control sfGFPproducing CFPS reactions were rehydrated with nuclease free water (grey bar, 0% human body fluid).
CFPS reaction extract composition was 50% (v/v) regular BL21-Star (DE3) extract (fermented at 37 °C)
and 50% m-RI + pOFX extract fermented at 24 °C in absence of DTT. Error bars represent one standard
deviation for n ≥ 3. B) RNase A equivalent activity of the native CFPS reaction (no m-RI extract, grey
bar) and three human fluids of saliva (blue bar), serum (orange bar), and urine (green bar) as determined
by the RNase Alert Kit (ThermoFisher Scientific). Error bars represent one standard deviation for n ≥ 3.

The optimized CFPS system performed best in human saliva, retaining ~25% of the
original CFPS protein production capability at 100% saliva. Human serum and urine samples must
be diluted to some degree to retain significant CFPS activity. This is not unexpected considering
the varying RNase activities in human samples. As shown in Figure 4-8B, RNase activity in human
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serum and urine samples is ~4 to 5 times greater than human saliva samples and each human fluid
sample has greater RNase activity than that already present in E. coli-lysate-based CFPS. It should
be noted that prior work producing m-RI by CFPS (rather than during extract preparation) can be
used to supply even more m-RI than already supplied by the extract and retain higher CFPS yields
at higher concentrations of body fluids [185]. However, the streamlined method presented herein
to produce m-RI as part of the extract is sufficient for 100% saliva CFPS biosensors and CFPS
biosensors used with diluted serum and urine samples.

4.3.4

Saliva-based glutamine biosensor
To demonstrate the utility of the streamlined method for providing m-RI in the extract of

E. coli lysate-based CFPS biosensors in saliva, a recently reported CFPS glutamine biosensor [97]
was tested. Glutamine is a biomarker for a variety of disease and disorders including but not limited
to kidney disease, Alzheimer’s disease, depression, schizophrenia, brain dysfunction, and diabetes
[103, 170]. Recently, a serum-based glutamine CFPS biosensor has been reported where the extent
of reporter protein expression (sfGFP) correlates linearly with the concentration of glutamine in a
sample [97].
Despite successful determination of glutamine level in serum, this biosensor used
commercial m-RI, did not test lyophilization capability of the biosensor for on-demand
applications, and used serum which is less convenient to obtain than saliva. Here, a lyophilized
glutamine biosensor with human saliva was tested. For this work, the optimal 50/50 m-RI/regular
extract combination was used as the key reagent for the lyophilized biosensor and both water and
30% human saliva were tested with varying concentrations of added glutamine.
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Figure 4-9: Glutamine CFPS biosensor assay in deionized water (red dots) and 30% saliva in presence of
up to 200 µM externally added glutamine to the CFPS reactions. All reactions had 50% m-RI + pOFX
(grown at 24 °C, No DTT) and 50% regular BL21-Star extract. CFPS reactions were performed at 37 °C
for 3 h and sfGFP RFU was normalized to the background sfGFP RFU in absence of externally added
glutamine.

A similar strong linear increase in sfGFP production was observed for both water samples
(Figure 4-9, red dots) and human saliva (Figure 4-9, blue dots) when increasing concentrations of
glutamine was added. This suggests that the streamlined method for including m-RI in CFPS
biosensors could be effective to mitigate RNase activity and enable CFPS biosensing in human
body fluid samples.

4.4

Conclusion
RNase inhibitor is a critical reagent for CFPS biosensors when testing samples such as

human body fluids contain RNases. However, RNase inhibitor is the most expensive reagent of
E. coli-lysate based CFPS biosensors (increases the reagent costs by ~900%) [185]. Here we
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reported for the first time the optimization and production of m-RI as part of the E. coli-lysate used
in CFPS which essentially eliminates the RNase inhibitor cost (Figure 4-10).

Figure 4-10: Schematic representation of CFPS biosensor in presence of three human body fluids of
saliva, serum, and urine.

Optimal fermentation conditions to prepare extracts with m-RI were determined as 24 °C
and co-expression with GroEL/ES folding chaperones. However, to achieve both highly
productive CFPS with RNase inhibition activity, a 50/50 mixture of m-RI/regular extract
combination was found to be the optimal condition. This extract was combined with other CFPS
reagents, lyophilized for long-term storage and then assessed for its activity in three human body
fluids (saliva, serum, and urine). Finally, this extract was used to facilitate CFPS glutamine
biosensing in human saliva samples. The m-RI-containing CFPS extract developed in this work
has the potential to reduce CFPS costs by ~90% and enable streamlined production of low cost
CFPS biosensors to detect a variety of biomarkers in human body fluids.
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5

CONCLUSION AND FUTURE WORK
CFPS systems have the potential to transform biocatalysis immobilization and

biosensors/medical diagnostics due to their low cost, portability, ease-of-use, specificity, and
simplicity. Through the work presented in this dissertation, the biocatalysis immobilization and
biosensor fields of CFPS research have been furthered. As described below there is further
research to be completed, but with continued effort it is anticipated that CFPS-enabled biocatalysis
immobilization optimization and CFPS biosensors will have broad reaching commercial,
environmental, and health care impacts.

5.1

Conclusion and future work for site-specific covalent immobilization of enzymes.
Chapter 2 of this dissertation focused on developing a combined design heuristics and

coarse-grain simulation approach to find effective design heuristics and evaluate the importance
of the added computation in addition to finding top sites for covalent immobilization of TEM-1.
SASA, secondary structure, side-chain orientation, and bulkiness of the replaced residue were
among the tested design heuristics in this study. The thermal stability of variants and the stability
of 5 defined domains were predicted by a coarse-grain simulation. Interestingly, the nucleotide
following the amber stop codon substitution (4th nucleotide) was a statistically significant
predictor of the expression level of TEM-1 variants. Moreover, the relative stability of each
structured domain of TEM-1, as determined by a coarse grain simulation, was predictive of the
impact of incorporating the AzF on the activity of TEM-1 variants. This study showed that the
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combined heuristic approach applied herein was correlated well enough to predict the top three
optimal immobilization sites for TEM-1 βlactamase.
Considering the decrease in specific activity when TEM-1 was immobilized over a
hydrophilic surface (agarose) covered by hydrophobic DBCO groups, we hypothesized that
changing the hydrophobicity of the surface could improve the activity of immobilized enzyme.
Replacement of AzF with p-propargyloxyphenylalanine (pPaF) and DBCO with alkyne (available
from Click Chemistry Tools) can address this issue. However, pPaF has even lower solubility in
water and a copper-based click chemistry should be used [114], which necessitates working in an
anaerobic chamber.
Additionally, other industrially important enzymes could be considered for site-specific
covalent immobilization. LCC is a promising candidate considering its role as an environmentally
friendly enzyme for the degradation of Polyethylene terephthalate (PET) plastics [198, 199].
Preliminary results showed high soluble expression of this enzyme, and its activity was tested and
confirmed. Design heuristics of SASA and the distance of replaced residues to the active sites were
not considered fully for TEM-1 immobilization which can be considered for LCC.
The stability of domains for the replaced residues was found to be an important parameter
in determining the tolerance of TEM-1 to site-specific substitution with AzF. More work with
other enzymes is needed to validate this effect. However, there might be some limitations of using
this parameter as enzymes fold and are stabilized in diverse manners. While the coarse grain
simulation results are impressive in their predictive capability and in assisting researchers
understand of the stabilization mechanisms in individual enzymes, the extent to which this can
reliably be applied to the myriad enzymes of nature has yet to be established. Thus, more enzymes
need to be simulated and screened to further validate and fine-tune the predictive model.
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As discussed previously, the thermal shift assay could not be used because the agarose beads
interfere with the signal and the chemical stability of free and immobilized variants was utilized
to determine the post-immobilization stability of TEM-1 variants. The inconsistent thermal
stability predictions (by coarse-grain simulation) and the experimentally determined chemical
stability could be addressed by using another method to directly determine the thermal stability of
immobilized enzymes such as Isothermal Titration Calorimetry (ITC) [200, 201]. This approach
could be beneficial in the future to fine-tune the predictive capabilities of the course-grain model.

5.2

Conclusion and future work for RNase inhibitor synthesis with CFPS
In chapter 3, flexibility and open nature of CFPS systems were used to produce a difficult

to express mammalian protein (murine RNase inhibitor or m-RI) in E. coli. m-RI is one of the most
expensive and critical reagents for biosensors that work with human body fluids for the detection
of various biomarkers related to diseases or disorders.
In addition to optimizing soluble expression yield of m-RI by manipulating several
variables such as redox potential, reaction temperature, reaction time, and presence of chaperones,
the activity and stability of this protein were determined by another CFPS reaction. The
lyophilization capability of CFPS produced m-RIs were tested with three human body fluids. This
study decreased the cost of such biosensors by ~90% (Appendix B) which further encourages the
application of CFPS biosensors for diagnostic and treatment purposes.
By drastically reducing the costs of CFPS biosensors, it is possible to maintain a very
inexpensive CFPS biosensor while adding some cost for a colorimetric reporter system that would
enable at-home use.

For future work, changing the reporter protein from sfGFP to a
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bioluminescent reporter such as luciferase or a colorimetric reporter such as β-lactamase, or βgalactosidase will be considered.
The applicability of other non-invasive human body fluids such as sweat and tears could also
be investigated for CFPS-based biosensors. Sweat could be utilized to monitor a variety of
biomarkers such as drugs, ethanol, hormones, immune biomarkers, minerals, and glucose using
wearable patches [202-206]. It should be mentioned that CFPS biosensors have been lyophilized
and stabilized on different types of paper by our lab and other labs before [90, 207] which supports
the likelihood of successful development of these types of biosensors. Tears are more difficult to
collect than other non-invasive human body fluids (urine, saliva, and even sweat), but this human
body fluid provides a variety of biomarkers that are clinically useful for diagnostics or monitoring
purposes. Tear-based biosensors have been demonstrated for diabetes, ocular surface diseases and
allergies, Alzheimer’s disease, dry eye disease, Keratoconus, Trachoma infection, and Cystic
fibrosis [208-210].

5.3

Conclusion and future work for in situ RNase production during CFPS extract
preparation
Chapter 4 was an extension of chapter 3 which aimed to streamline the preparation of m-RI

and remove the additional step of producing m-RI in a prior CFPS reaction and then adding it to
the CFPS biosensor. This was accomplished by preparing an extract with RNase inhibition activity
to be utilized in CFPS biosensors. Despite preparing an extract with RNase inhibition activity, the
overall productivity of extract decreased, which was addressed by combining m-RI extract and
regular BL21-Star extract. The applicability of a combined extract was determined by CFPS
reactions working with human body fluids. Despite lower RNase inhibition activity of this m-RI-
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extract-based system compared to the CFPS produced m-RI (which highlights further the
advantages of less crowded, more controllable CFPS systems), this extract preparation was easier
to make and less resource intensive. For future work, preparation of an extract with RNase
inhibition activity and high regular productivity could be considered. Manipulation of the extract
preparation method including changing induction OD600, Harvest OD, and expressing m-RI under
the control of another inducer could help maximize m-RI activity while minimizing loss of CFPS
activity.
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Appendix A
pTwist TEM-1 Sequence. The TEM-1 β-lactamase (PDB: 1XPB) sequence is underlined and
highlighted green. The C-terminus Strep-tag II sequence is bolded and underlined. The KanR
sequence is italicized and highlighted in yellow. The M13 promoter and terminator sequences are
in red.
TAATACGACTCACTATAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTTAACTTT
AAGAAGGAGATATACATATGCATCCGGAAACACTGGTGAAAGTTAAAGATGCCGAAGATCA
GCTGGGTGCACGTGTTGGTTATATTGAACTGGATCTGAATAGCGGCAAAATCCTGGAAAGTT
TTCGTCCGGAAGAACGCTTTCCGATGATGAGCACCTTTAAAGTTCTGCTGTGTGGTGCAGTTC
TGAGCCGTGTTGATGCAGGTCAAGAACAGCTGGGACGTCGTATTCATTATAGCCAGAATGAT
CTGGTTGAATATAGTCCGGTTACCGAAAAACATCTGACCGATGGTATGACCGTTCGTGAACT
GTGTAGCGCAGCAATTACCATGAGCGATAATACCGCAGCAAATCTGCTGCTGACCACCATTG
GCGGTCCGAAAGAACTGACCGCATTTCTGCATAATATGGGTGATCATGTTACCCGTCTGGAT
CGTTGGGAACCTGAACTGAATGAAGCAATTCCGAATGATGAACGTGATACCACCATGCCTGC
AGCAATGGCAACCACACTGCGTAAACTGCTGACCGGTGAACTGTTAACCCTGGCAAGCCGTC
AGCAGCTGATCGATTGGATGGAAGCAGATAAAGTTGCAGGTCCGCTGCTGCGTAGCGCACT
GCCTGCAGGTTGGTTTATTGCAGATAAAAGCGGTGCCGGTGAACGTGGTAGCCGTGGTATTA
TTGCCGCACTGGGTCCTGATGGTAAACCGAGCCGTATTGTTGTGATTTATACCACCGGTAGC
CAGGCAACCATGGATGAACGTAATCGTCAGATTGCAGAAATTGGTGCAAGCCTGATTAAAC
ATTGGTGGAGCCACCCGCAGTTCGAAAAATAAGTCGACCGGCTGCTAACAAAGCCCGAAA
GGCTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGAGGCTAGGTGGA
GGCTCAGTGATGATAAGTCTGCGATGGTGGATGCATGTGTCATGGTCATAGCTGTTTCCTGT
GTGAAATTGTTATCCGCTCAGAGGGCACAATCCTATTCCGCGCTATCCGACAATCTCCAAGA
CATTAGGTGGAGTTCAGTTCGGCGTATGGCATATGTCGCTGGAAAGAACATGTGAGCAAAA
GGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCC
GCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGG
ACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCT
GCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTC
ACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAAC
CCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTA
AGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATG
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TAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGT
ATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGAT
CCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGC
AGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCTATTCAA
CAAAGCCGCCGTCCCGTCAAGTCAGCGTAAATGGGTAGGGGGCTTCAAATCGTCCGCTCTGC
CAGTGTTACAACCAATTAACAAATTCTGATTAGAAAAACTCATCGAGCATCAAATGAAACTGCAA
TTTATTCATATCAGGATTATCAATACCATATTTTTGAAAAAGCCGTTTCTGTAATGAAGGAGAAAACTC
ACCGAGGCAGTTCCATAGGATGGCAAGATCCTGGTATCGGTCTGCGATTCCGACTCGTCCAACATC
AATACAACCTATTAATTTCCCCTCGTCAAAAATAAGGTTATCAAGTGAGAAATCACCATGAGTGACGA
CTGAATCCGGTGAGAATGGCAAAAGCTTATGCATTTCTTTCCAGACTTGTTCAACAGGCCAGCCATT
ACGCTCGTCATCAAAATCACTCGCATCAACCAAACCGTTATTCATTCGTGATTGCGCCTGAGCGAGA
CGAAATACGCGATCGCTGTTAAAAGGACAATTACAAACAGGAATCGAATGCAACCGGCGCAGGAAC
ACTGCCAGCGCATCAACAATATTTTCACCTGAATCAGGATATTCTTCTAATACCTGGAATGCTGTTTT
CCCGGGGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTACGGATAAAATGCTTGATGGTCG
GAAGAGGCATAAATTCCGTCAGCCAGTTTAGTCTGACCATCTCATCTGTAACATCATTGGCAACGCT
ACCTTTGCCATGTTTCAGAAACAACTCTGGCGCATCGGGCTTCCCATACAATCGATAGATTGTCGCA
CCTGATTGCCCGACATTATCGCGAGCCCATTTATACCCATATAAATCAGCATCCATGTTGGAATTTA
ATCGCGGCCTCGAGCAAGACGTTTCCCGTTGAATATGGCTCATAACACCCCTTGTATTACTGTTT
ATGTAAGCAGACAGTTTTATTGTTCATGATGATATATTTTTATCTTGTGCAATGTAACATCAG
AGATTTTGAGACACAACGTGGCTTTCCCCCGCCGCTCTAGAACTAGTGGATCCAAATAAAAC
GAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTCGCATTATACGAGAC
GTCCAGGTTGGGATACCTGAAACAAAACCCATCGTACGGCCAAGGAAGTCTCCAATAACTG
TGATCCACCACAAGCGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTCATG
CATAATCCGCACGCATCTGGAATAAGGAAGTGCCATTCCGCCTGACCT
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Table A-1. Primer sequences for the Amber stop codon substitution for the 17 selected sites of
TEM-1. The substituted nucleotides are in red
TEM-1

Forward primer sequence

Reverse primer sequence

N154

GCATTTCTGCATTAGATGGGTGATCATGTTACCCGTCTG

CCCATCTAATGCAGAAATGCGGTCAGTTCTTTCG

Q269

CACCGGTAGCTAGGCAACCATGGATGAACGTAATCG

TGCCTAGCTACCGGTGGTATAAATCACAACAATACG

Q88

GTTGATGCAGGTTAGGAACAGCTGGGACGTCGTATTC

TCTTGCTATGCATCAACACGGCTCAGAACTGCAC

E197

GCTGACCGGTTAGCTGTTAACCCTGGCAAGCCGTCAGC

AACAGCTAACCGGTCAGCAGTTTACGCAGTGTG

K192

CACACTGCGTTAGCTGCTGACCGGTGAACTGTTAAC

AGCAGCTAACGCAGTGTGGTTGCCATTGCTG

E28

CATATGCATCCGTAGACACTGGTGAAAGTTAAAGATGCCG

AGTGTCTACGGATGCATATGTATATCTCCTTCTTAAAGTT

A227

CGCACTGCCTTAGGGTTGGTTTATTGCAGATAAAAGCGG

CAACCCTAAGGCAGTGCGCTACGCAGCAGC

L201

GTGAACTGTTAACCTAGGCAAGCCGTCAGCAGCTGATC

CTTGCCTAGGTTAACAGTTCACCGGTCAGCAGTTTA

G87

CGTGTTGATGCATAGCAAGAACAGCTGGGACGTCGTATTC

TCTTGCTATGCATCAACACGGCTCAGAACTGCA

E281

CGTCAGATTGCATAGATTGGTGCAAGCCTGATTAAACATTG

CCAATCTATGCAATCTGACGATTACGTTCATCCATG

P62

GGAAAGTTTTCGTTAGGAAGAACGCTTTCCGATGATGAG

CTTCCTAACGAAAACTTTCCAGGATTTTGCCGC

T114

CGAAAAACATCTGTAGGATGGTATGACCGTTCGTGAACTG

CCATCCTACAGATGTTTTTCGGTAACCGGACTATATTC

D254

CACTGGGTCCTTAGGGTAAACCGAGCCGTATTGTTGTG

TTACCCTAAGGACCCAGTGCGGCAATAATACCAC

R93

GAACAGCTGGGATAGCGTATTCATTATAGCCAGAATGATC

ATACGCTATCCCAGCTGTTCTTGACCTGCATCAAC

S52

CTGGATCTGAATTAGGGCAAAATCCTGGAAAGTTTTC

TTGCCCTAATTCAGATCCAGTTCAATATAACCAAC

R43

GCTGGGTGCATAGGTTGGTTATATTGAACTGGATCTGAAT

CCAACCTATGCACCCAGCTGATCTTCGGCATC

N175

GAAGCAATTCCGTAGGATGAACGTGATACCACCATGCCTG

TCATCCTACGGAATTGCTTCATTCAGTTCAGGTTC

Variant

Figure A-1: Effect of 4th nucleotide type on total TEM-1 expression yield for Purines (U) or Pyrimidines
(Y) (p=0.026).
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Figure A-2: Effect of A) SASA, B) Side-chain orientation, C) Secondary structure, D) Domain, and E)
Residue bulkiness on TEM-1 expression yield (in µg/ml). All P values in t-tests were greater than 0.05.
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Figure A-3: Correlation between the percentage of solubility of TEM-1 variants containing AzF (ratio of
soluble to total yield) and their specific activity before immobilization (in µM Product/ng Enzyme).
R2=0.88 and y=98.231x
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Figure A-4: Effect of A) Secondary structure, B) SASA, and C) Residue bulkiness on TEM-1 specific
activity before immobilization (in µM Product/ng Enzyme/min). All P values in t-tests were greater than
0.05.
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Figure A-5: Effect of A) Secondary structure, B) SASA, C) Side-chain orientation, D) Residue bulkiness,
and E) Domain on TEM-1 immobilization yield (in mg Enzyme/g beads). All P values in t-tests were
greater than 0.05.
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Figure A-6: Specific activity of TEM-1 variants containing AzF (in µM Product/ng Enzyme/min) before
(black bars) and after (white bars) urea treatment (6 M urea) at 37 °C for 30 min. Error bars represent one
standard deviation for at least 3 reactions. TEM-1 activities for all variants after urea treatment were not
significantly higher than the background and all variants were concluded to be inactive.
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Figure A-7: Correlation between percent solubility of mutants and the ratio of specific activity after urea
incubation to activity before urea incubation. Y=1.087x and R2=0.95
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Figure A-8: Comparison of experimental stability of the immobilized TEM-1 variants and the coarsegrain simulation for a slightly hydrophobic surface or a hydrophobic surface [125].
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Appendix B
Cost analysis of CFPS Biosensors. The total cost of E. coli-lysate-based CFPS reaction without
m-RI was estimated to be $2.8/ml CFPS (or 0.14 USD for a 50 µl CFPS biosensor) based on the
mentioned reagents and vendors in the Methods section and for preparing the extract, in-house.
The costs of labor, equipment, and m-RI activity validation were not considered in our cost
analysis estimate of the in-house CFPS reactions. As has been recommended by the commercial
m-RI vendor (NEB- Cat.# M0314S, Ipswich, MA), 1U/µl reaction was the final m-RI amount in
CFPS reaction which estimated to be $1.22 for 50 µl CFPS reaction. This increases the cost of one
CFPS biosensor (50 µl volume) from $0.14 to $1.36 for including the commercial m-RI (nearly
10 times). However, using 6 ng/µl in-house m-RI instead of the commercial m-RI, would require
~1.2 µl CFPS-produced m-RI (with an average 250 µg/ml soluble expression yield) which means
only $0.003 per 50 µl CFPS biosensor (~99.8% reduction in m-RI cost). By utilizing CFPSproduced m-RI instead of the commercial m-RI, we decrease the overall cost of every 50 µl CFPS
biosensor from $1.36 to $0.14 (~90% reduction in overall cost) which is considerable when making
affordable, on-demand biosensors for worldwide distribution.
pTwist murine RNase Inhibitor (m-RI) Sequence. The m-RI sequence (PDB ID: 3TSR) is
underlined and highlighted green. The KanR sequence is highlighted in yellow. The T7 promoter
and T7 terminator sequences are bolded and in red.
ATTAATACGACTCACTATAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTTAA
CTTTAAGAAGGAGATATACATATGAGCCTGGATATTCAGTGTGAACAGCTGAGTGATGCACG
TTGGACCGAACTGCTGCCGCTGATTCAGCAGTATGAAGTTGTTCGTCTGGATGATTGTGGTCT
GACCGAAGTTCGTTGTAAAGATATTAGCAGCGCAGTTCAGGCAAATCCGGCACTGACAGAA
CTGAGCCTGCGTACCAATGAATTAGGTGATGGTGGTGTTGGTCTGGTTCTGCAGGGTTTACA
GAATCCGACCTGTAAAATTCAGAAACTGTCACTGCAGAATTGCGGTTTAACCGAAGCAGGTT
GTGGTATTCTGCCTGGTATGCTGCGTAGCCTGAGCACCCTGCGTGAACTGCATCTGAATGAT
AATCCGATGGGTGATGCAGGTCTGAAACTGCTGTGTGAAGGCCTGCAGGATCCGCAGTGTCG
TCTGGAAAAACTGCAGTTAGAATATTGTAATCTGACCGCAACCAGCTGTGAACCGCTGGCAA
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GCGTTCTGCGTGTTAAAGCAGATTTTAAAGAACTGGTGCTGAGCAACAATGATCTGCATGAA
CCGGGTGTTCGTATTCTGTGTCAGGGTCTGAAAGATAGCGCATGTCAGCTGGAAAGCCTGAA
ACTGGAAAATTGTGGTATTACCGCAGCAAATTGCAAAGACCTGTGTGATGTTGTTGCCAGCA
AAGCAAGCCTGCAAGAACTGGATCTGAGTAGCAATAAACTGGGTAATGCCGGTATTGCAGC
CCTGTGTCCTGGTCTGCTGCTGCCGAGCTGTAAACTGCGTACCCTGTGGCTGTGGGAATGTG
ATATTACAGCCGAAGGCTGTAAAGACCTGTGTCGTGTGCTGCGTGCAAAACAGTCTCTGAAA
GAGCTGAGTCTGGCAAGCAATGAACTGAAAGATGAAGGTGCACGTCTGCTGTGCGAAAGTC
TGCTGGAACCGGGTTGCCAACTGGAATCACTGTGGATTAAAACCTGTAGCCTGACCGCAGCA
TCATGTCCGTATTTCTGTAGCGTTCTGACCAAAAGCCGTAGCCTGCTGGAATTACAGATGAG
CAGCAACCCGCTGGGTGATGAAGGCGTTCAAGAACTGTGTAAAGCACTGAGCCAGCCGGAT
ACCGTTCTGCGCGAACTGTGGTTAGGTGATTGTGATGTGACCAATAGCGGTTGTAGCAGCCT
GGCAAATGTTCTGCTGGCAAATCGTAGTCTGCGCGAGCTGGATCTGTCAAATAATTGTATGG
GTGGTCCGGGTGTGCTGCAGCTGCTGGAAAGTTTAAAACAGCCGAGCTGCACCCTGCAGCA
GCTGGTTCTGTATGATATCTATTGGACCAATGAAGTGGAAGAACAGCTGCGTGCCCTGGAAG
AAGAACGTCCGAGTCTGCGTATTATTAGCTAAGTCGACCGGCTGCTAACAAAGCAACTAGC
ATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGAGAGGCTAGGTGGAGG
CTCAGTGATGATAAGTCTGCGATGGTGGATGCATGTGTCATGGTCATAGCTGTTTCCTGTGTG
AAATTGTTATCCGCTCAGAGGGCACAATCCTATTCCGCGCTATCCGACAATCTCCAAGACAT
TAGGTGGAGTTCAGTTCGGCGTATGGCATATGTCGCTGGAAAGAACATGTGAGCAAAAGGC
CAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCC
CCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTA
TAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCG
CTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGC
TGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCC
CGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGAC
ACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGG
CGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTG
GTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGC
AAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAA
AAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCTATTCAACAAAG
CCGCCGTCCCGTCAAGTCAGCGTAAATGGGTAGGGGGCTTCAAATCGTCCTCGTGATACCAA
TTCGGAGCCTGCTTTTTTGTACAAACTTGTTGATAATGGCAATTCAAGGATCTTCACCTAGAT
CCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTG
ACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCA
TAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCC
AGTGCTGCAATGATACCGCGAGAGCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCA
GCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTA
TTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTT
GCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGT
TCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTT
CGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAG
CACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACT
CAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATA
CGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTC
GGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTG
CACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGA
AGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCT
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TCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTG
AATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCAGA
TACCTGAAACAAAACCCATCGTACGGCCAAGGAAGTCTCCAATAACTGTGATCCACCACAA
GCGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTCATGCATAATCCGCACG
CATCTGGAATAAGGAAGTGCCATTCCGCCTGACCT

Table B-1: Primer sequences used for inserting 6xHis-tag in the N or C-terminal of m-RI insert
gene.
N-terminus
6xHis-tag
C-terminus
6xHis-tag

A

Forward (5’ to 3’)
TATACATATGCATCACCATCACCA
TCACAGCCTGGATATTCAGTGTGA
ACAGCTG
GCGTATTATTAGCCATCACCATCA
CCATCACTAAGTCGACCGGCTGCT
AACAAAG

Native CFPS condition

B
100

80

% sfGFP expression

% Soluble m-RI Yield

CGACTTAGTGATGGTGATGGTGATGGCTAAT
AATACGCAGACTCGGACG

12 mM DTT

100

60
40

Native CFPS condition

12 mM DTT addition

NEB (1U)

Control, No saliva

No m-RI

80
60
40
20

20
0

Reverse (5’ to 3’)
CCAGGCTGTGATGGTGATGGTGATGCATATGT
ATATCTCCTTCTTAAAGTTAAACA

0
No tag

C-His tag

N-His tag

m-RI Form

No Tag

C-His Tag N-His Tag

NEB
(1U/μl)
m-RI Form

No m-RI

No saliva
or m-RI
control

Figure B-1: A) Relative soluble expression yields for three m-RI preparations without tag, Cterminal His-tag, and N-terminal His-tag in the native CFPS condition without additives (blue
bars) or in presence of 12 mM DTT (green bars). All soluble yields are reported relative to the
highest soluble expression of m-RI (No tag, 12 mM DTT). All reactions were performed in
triplicates and at 24 °C, after 2 h, 280 RPM using pOFX extract. (B) Testing m-RI activity of
three m-RI preparations (3 ng/µl) of m-RI without tag, C-His tag, and N-His tag for sfGFP
expression in presence of 30% saliva after 3 h at 37 °C. m-RIs were expressed at native CFPS
reduced condition (blue bars) or in presence of 12 mM DTT (green bars). Control CFPS reaction
by using 1 U/µl NEB m-RI is shown by a grey bar and the control without saliva or m-RI is
shown by a yellow bar. Control CFPS reaction in presence of 30% saliva and absence of m-RI is
shown by a red bar and all expression levels were normalized according to it.
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Figure B-2: m-RI activity after one freeze-thaw cycle. m-RIs expressed at 15 °C- 2 h (blue), 15
°C- 6 h (yellow), and 24 °C- 2 h (green) with 3 ng/µl (solid colors), 2 ng/µl (diagonal stripes),
and 1 ng/µl (horizontal stripes) soluble m-RI concentrations. All m-RIs were expressed by pOFX
extract. RNase inhibition activity of NEB-m-RI is shown in purple and the No saliva/m-RI
control is in grey.
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Figure B-3) SDS-PAGE gel for 1) WT pOFX, 2) m-RI + pOFX, 3) m-RI + BL21-Star, and 4)
WT BL21-Star cell-lysates before (a) or after (b) centrifugation at 13,000 g, 30 min, and 4 °C.
Each lysate was diluted 50x before loading for better visualization. Color prestained protein
marker (10-250 kDa, NEB, Cat.# P7719S Ipswich, MA) was used as protein marker and 1.25 µl
commercial m-RI (NEB, Ipswich, MA) was used as a comparison with the in-house m-RI
overexpressed in the extracts. While a significantly darker protein band at ~50 kDa in lanes 2a
and 3a provide evidence of m-RI overexpression in cells which harbor the plasmid for m-RI
expression, this band weakens significantly after the centrifugation step of extract preparation
(lanes 2b and 3b). This suggest that a significant portion of m-RI aggregates even when
GroEL/ES is overexpressed. Also, GroEL/ES expression (darker bands shown in langes 1a and
1b) diminishes to the point where it is difficult to observe by SDS-PAGE when coexpressed with
m-RI (compare lanes 2a and 2b to 1a and 1b). This suggests that future optimization could be
performed to achieve even higher GroEL/ES expression levels relative to m-RI which may lead
to higher m-RI solubilities and higher m-RI concentrations and activities in the final centrifuged
extracted used with CFPS.
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